

Toward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic

Carsten Weiss,^{*,#} Marie Carriere,^{*,#} Laura Fusco,[#] Ilaria Capua, Jose Angel Regla-Nava, Matteo Pasquali, James A. Scott, Flavia Vitale, Mehmet Altay Unal, Cecilia Mattevi, Davide Bedognetti, Arben Merkoçi, Ennio Tasciotti, Açelya Yilmazer, Yury Gogotsi, Francesco Stellacci, and Lucia Gemma Delogu^{*}



Cite This: *ACS Nano* 2020, 14, 6383–6406



Read Online

ACCESS |

Metrics & More

Article Recommendations

ABSTRACT: The COVID-19 outbreak has fueled a global demand for effective diagnosis and treatment as well as mitigation of the spread of infection, all through large-scale approaches such as specific alternative antiviral methods and classical disinfection protocols. Based on an abundance of engineered materials identifiable by their useful physicochemical properties through versatile chemical functionalization, nanotechnology offers a number of approaches to cope with this emergency. Here, through a multidisciplinary Perspective encompassing diverse fields such as virology, biology, medicine, engineering, chemistry, materials science, and computational science, we outline how nanotechnology-based strategies can support the fight against COVID-19, as well as infectious diseases in general, including future pandemics. Considering what we know so far about the life cycle of the virus, we envision key steps where nanotechnology could counter the disease. First, nanoparticles (NPs) can offer alternative methods to classical disinfection protocols used in healthcare settings, thanks to their intrinsic antipathogenic properties and/or their ability to inactivate viruses, bacteria, fungi, or yeasts either photothermally or *via* photocatalysis-induced reactive oxygen species (ROS) generation. Nanotechnology tools to inactivate SARS-CoV-2 in patients could also be explored. In this case, nanomaterials could be used to deliver drugs to the pulmonary system to inhibit interaction between angiotensin-converting enzyme 2 (ACE2) receptors and viral S protein. Moreover, the concept of “nanoimmunity by design” can help us to design materials for immune modulation, either stimulating or suppressing the immune response, which would find applications in the context of vaccine development for SARS-CoV-2 or in counteracting the cytokine storm, respectively. In addition to disease prevention and therapeutic potential, nanotechnology has important roles in diagnostics, with potential to support the development of simple, fast, and cost-effective nanotechnology-based assays to monitor the presence of SARS-CoV-2 and related biomarkers. In summary, nanotechnology is critical in counteracting COVID-19 and will be vital when preparing for future pandemics.



COVID-19: SETTING THE SCENE FOR NANOTECHNOLOGY

Through millions of years of evolution, viruses have gained a variety of molecular mechanisms for entry into cells; long-term survival within cells; and activation, inhibition, or modification of the host defense mechanisms at all levels.¹ Their ability to transfer genes with high efficiency inspired the development of noninfectious recombinant viral vectors for gene-therapy applications, beginning in 1990.^{2–4} Efforts were then underway to improve the safety of viral vectors, including developing nonviral drug-delivery systems inspired by the natural capabilities of viruses. Researchers in the field of nanomedicine have designed a variety of nanosystems that can mimic the gene-transfer capacity and high infectivity of viral vectors. By learning the molecular mechanisms behind these vectors, nanomedicine and biomedical researchers have developed delivery systems

used in different fields, including cancer therapy and regenerative medicine.^{5,6} However, nanotechnology is not only inspired by virology to develop novel delivery tools but also at the forefront in combatting dangerous viruses.

Nanotechnology is not only inspired by virology to develop novel delivery tools but also at the forefront in combatting dangerous viruses.

Published: June 10, 2020

Viral infections are one of the leading causes of morbidity and mortality worldwide and one of the main reasons for significant economic losses.^{7–9} Standard treatment approaches mainly rely on vaccination and therapeutics derived through targeting key processes in the virus life cycle. However, many viruses evolve subject to selective pressures, often becoming drug resistant, which necessitates additional resources for the development of new drugs.

A novel coronavirus causing pneumonia was identified in China in December 2019. On February 11, the Coronavirus Study Group (CGS) of the International Committee on Virus Taxonomy (ICTV) designated the virus as SARS-CoV-2 based on phylogeny and taxonomy.¹⁰ The same day, the Director General of the World Health Organization (WHO) designated the disease caused by SARS-CoV-2 “coronavirus disease 2019” (COVID-19). On March 11, 2020, the WHO declared the COVID-19 outbreak a pandemic. As of May 2020, SARS-CoV-2 has spread across the world in over 185 countries, with millions of infections and hundreds of thousands of deaths.¹¹

The main symptoms of COVID-19 are fever (85.6%), cough (68.7%), and fatigue (39.4%). Other less common symptoms include dyspnea, headache, loss of appetite, panting, sore throat, vomiting, diarrhea, rhinorrhea, and abdominal pain. The severity of disease in patients depends mainly on the presence of comorbidities such as hypertension, diabetes, and coronary heart disease.^{12,13} The incubation period is reported to be between 5 and 14 days before disease onset.¹⁴ Recent reports indicate that some COVID-19 patients exhibit damage in other organs such as the heart, kidney, eye (conjunctivitis), and brain (encephalitis).^{15–18} The race is on to develop drugs and treatment options to combat COVID-19, harnessing all of the tools and technologies modern molecular medicine can offer.

The genome of SARS-CoV-2 has been fully sequenced¹⁹ and shows a high degree of similarity in key genes with other coronaviruses causing respiratory diseases such as SARS-CoV.²⁰ Based on knowledge gathered during the SARS-CoV epidemic, a key target of the virus includes the surface receptor in human cells, angiotensin-converting enzyme II (ACE2), which is required for efficient uptake in host cells.^{19,21–23}

The C-terminal domain (*i.e.*, receptor-binding domain) of the envelope-embedded spike (S) 1 protein of SARS-CoV-2 binds ACE2. The molecular details of this interaction have been provided by solving the crystal structure of the complex.²⁴ Because binding of the S protein to ACE2 is critical for the first steps of infection, the most common treatment approaches focus on disrupting this key event. At present, there are three main strategies to block ACE2 binding: (i) administration of soluble, recombinant ACE2 protein, which acts as a decoy receptor to scavenge the virus and, thus, to prevent uptake into host cells;²¹ (ii) vaccination with antibodies that specifically bind to the S protein and interfere with ACE2 interaction; and (iii) inhibition of host proteases that process the S protein and are essential for ACE2 binding and subsequent membrane fusion to enable intracellular delivery of the virus.²³

As shown in Figure 1, the first events of the infection (*i.e.*, the interactions of the virus with the target cells expressing ACE2) are in the process of being elucidated at the molecular level. However, as patients suffering from severe symptoms—which usually develop only after several days or a week—already bear a high viral load in the lungs, there is a pressing need for strategies not only to prevent infection of the host cells but also to attack pre-existing persistent viruses and to prevent life-threatening processes, such as hyperinflammation in the lung and multiple-




Figure 1. SARS-CoV-2 viral life cycle and potential targets for nanomaterials. SARS-CoV-2 binds to angiotensin-converting enzyme 2 (ACE2) receptors on the host cell surface. Transmembrane serine protease 2 (TMPRSS2) facilitates cellular entry through protease activity. Later, viral particles are internalized and enter into endosomes. Due to the low pH of endosomes, viral particles are uncoated and the viral genome is released for protein synthesis. Following viral RNA and protein synthesis, new infectious particles are assembled and released.

organ failure.²⁵ Notably, a comprehensive protein–protein interaction (PPI) map of most viral proteins with the human proteome has been established to provide potentially novel targets for treatment employing already U.S. Food and Drug Administration (FDA)-approved drugs *via* a process known as drug repurposing.²⁶

The development process of antiviral therapies typically requires years before the therapies can be made widely available²⁷ because there are a number of regulatory steps required to establish the safety and efficacy of vaccines and drugs.²⁸ Moreover, the highly specific viral targets might change as SARS-CoV-2 continues to mutate, resulting in resistance to medication, such as has been observed when attempting to treat other viral infections. Overviews of the identification of candidate drugs for SARS-CoV-2 are detailed in refs 29–31.

In the past decade, there has been growing interest in novel, broad-spectrum antiviral compounds, which might be less prone to resistance and could be employed against a wide class of different viruses, including new variants.^{32–34} Importantly, such therapies could be prescribed until more sophisticated, targeted drugs and vaccines are available for each new emerging virus.

Nanotechnology offers a number of solutions to fight viruses, both outside and inside the host, and several nanotechnology-based platforms have already been successful in preclinical studies to counter several human viral pathogens such as HIV, human papilloma virus, herpes simplex, and respiratory viruses.^{32–35} Nanotechnology-based approaches should be leveraged to help the fight against COVID-19 as well as any future pandemics, in a number of ways, including (i) novel vaccines and drugs, where nanomaterials can be leveraged for direct delivery of broad-spectrum antivirals and to support




Figure 2. Nanomaterials for prevention and therapy of COVID-19. Integrating nanomaterials into personal protective equipment (PPE) can prevent the entrance of SARS-CoV-2 in the respiratory system. Nanomaterials could also be used to deliver drugs to the pulmonary system *via* inhalators. Cellular binding of viral particles at the alveoli can be inhibited using targeted nanoparticles (NPs) against angiotensin-converting enzyme 2 (ACE2) receptors or viral S protein. Various mechanisms can be used to inactivate viral particles systemically such as using neutralizing NPs or photocatalytic nanomaterials. Nanomaterial-based vaccines or immunomodulation can be used to prevent SARS-CoV-2 infection or even to boost the immune response during infection. PDT, photodynamic therapy.

targeted therapies to the lungs; (ii) highly specific, rapid, and sensitive tests to detect infection or to detect immunity (serological tests); (iii) superfine filters for face masks or blood filtering; (iv) novel surfaces or surface coatings that are resistant to viral adhesion and can inactivate the virus; and (v) the improvement of tools for contact tracing (Figure 2).

This crisis has also highlighted the importance of rapid prototyping/manufacturing for addressing unforeseen needs, such as in case of a pandemic, where large-scale production of equipment including ventilators and personal protective equipment (PPE) is urgently needed and nanotechnology may aid (*e.g.*, in providing readily synthesizable materials for equipment manufacturing as well as for the improvement of their efficiency and durability). In the next sections, we expand and elaborate on the specific contributions that nanotechnology can offer to counter COVID-19 and similar pandemics.

NANOTECHNOLOGY TOOLS TO INACTIVATE SARS-CoV-2 IN PATIENTS

The main target of SARS-CoV-2 is the respiratory tract (upper airways, lung),³⁶ although other organs might also be infected (*e.g.*, gut, kidney) and vasculature²¹ also appears to be a prime target. The expression of ACE2 probably determines uptake by different tissues.³⁷

In addition to discussing immune-based approaches, because the lung is the most critically affected organ, we will center our discussion on the various options to inactivate the virus in the deep lung and to target the essential host cells for drug delivery. The virus reaches the alveoli and enters alveolar epithelial type II cells (AECII), due to the relatively high abundance of ACE2 and a permissive cellular milieu. These cells serve as a reservoir of the virus, which finally spreads throughout the lung, leading to the lung function impairment seen in severe cases. Airborne nanomaterials are optimally suited to penetrate into the deep lung due to the physicochemical properties of such aerosols, existing on the same size scale particles that penetrate most readily to the deep airways. Hence, nanomedicine is already

actively pursuing ideas to deliver drugs, therapeutic proteins, and mRNAs by exploiting nanodevices for pulmonary delivery.^{38,39}

Moreover, the rapid emergence of SARS-CoV-2 has exposed one of the main weaknesses in the current medical landscape: the lack of broad-spectrum antiviral drugs. At present, there are only a handful of approved antivirals, and they are mostly virus-specific. Hence, when a new virus emerges, little can be done pharmacologically to slow down its spread. Some research efforts have been focused on the development of broad-spectrum drugs, which could potentially offer some efficacy against future emerging viruses (and maybe SARS-CoV-2). The various approaches developed over the years are mainly based on the creation of entry inhibitors.^{40,41} A highly conserved part in viruses is the attachment ligand (VAL). In most known respiratory viruses,⁴² the VAL targets either heparan sulfate proteoglycans (HSPG)⁴³ or sialic acids (SA).⁴⁴ Both HSPG and SA mimics have shown *in vitro* ability to bind to viruses, blocking their interaction with cell membranes, and often in a broad-spectrum way.^{45–47}

In the context of nanomedicine, many nanomaterials have been developed, ranging from polymers⁴⁸ to dendrimers,⁴⁹ oligomers, NPs,⁵⁰ liposomes,⁵¹ and small molecules.⁵² However, successful clinical translation has been hindered by the fact that, upon dilution, these compounds lose efficacy as the virus-compound complex dissociates leaving viruses free to restart their replication cycle. Recently, it has been shown that this limitation can be overcome by synthesizing NPs that, after binding, are able to inhibit viral infectivity irreversibly by permanently damaging the virion, refueling the hope for a true, broad-spectrum antiviral drug.⁵³ Because the focus is also on the development of a drug specific to SARS-CoV-2, a good entry inhibitor could be based on blocking the S spike protein interaction with the cellular ACE2 receptor.^{19,21–23} Regardless of the specific approach, it is imperative that novel, effective antivirals be based on compounds that exhibit very low or negligible toxicity profiles, as patients will most likely need to

receive those drugs for extended periods of time and will already be weakened. For these reasons, when designing antiviral drugs, clearance mechanisms have to be kept in mind. An example of this process is the recent redesign of broad-spectrum antiviral NPs into equally effective modified cyclodextrins.⁵⁴ Moreover, nanotechnology may offer nanotherapeutic approaches to fill the existing gap between diagnostics and therapy.^{55–57} The simultaneous management of both diagnostics and therapy for those suffering from COVID-19 or in future pandemics, as for many other diseases, is an additional potential strategy to take into consideration in which nanomaterials have proven to be effective tools. The advantages of the capabilities of nanotechnology and nanomaterials for combined therapeutics and diagnostics has been widely explored in cancer research; however, there have been considerable efforts in the past few years to extend the scope of this approach to other areas including infectious diseases.⁵⁸

Nanomaterial-Based Vaccine Development and Immunomodulation. Following the publication of the genetic sequence of SARS-CoV-2 on January 11, 2020, intense research efforts have been devoted to developing a vaccine against COVID-19. With unprecedented speed, this extraordinary scientific mobilization led the first vaccine candidate to enter the Phase I human clinical trial on March 16, 2020, and other novel candidates are rapidly following.⁵⁹ Up to May 22, 2020, there are 10 COVID-19 candidate vaccines in clinical evaluations and 114 in preclinical development.⁶⁰

Concerning vaccine and immunization research, nanomaterials can assist in multiple ways to boost the upregulation required by the immune system and to direct the immune response specifically against antigens. Immune-targeted nanotherapeutics can be developed through their rational manufacture at the nanoscale level by designing nanomaterials that are able to amplify host's immune response, for instance as adjuvants in the context of vaccination.

Immune-targeted nanotherapeutics can be developed through their rational manufacture at the nanoscale level by designing nanomaterials that are able to amplify host's immune response, for instance as adjuvants in the context of vaccination.

The development of a vaccine will rely either on the direct administration of viral antigens (*e.g.*, in the form of recombinant proteins, vectored vaccines, or whole inactivated or attenuated virus) or RNA- or DNA-encoding viral antigens.²⁷ Candidate antigens for immunization are surface proteins such as the immunogenic spike protein (S1), which is already targeted by antibodies of convalescent patients.²⁷ Because the S1 protein is also essential for cellular uptake, many researchers are using this protein as the primary target for a vaccine.

There are many issues related to the delivery of a drug, protein, or RNA into the patient as the cargo is often degraded, not bioavailable, or is swiftly cleared. Nanotechnology provides multiple solutions to these challenges though, as nanocarriers can overcome some of these limitations.

Biocompatible polymeric-, lipid-based, or inorganic NPs can be tuned with respect to their physicochemical properties to encapsulate cargo proteins with high loading efficiency,

improving protein delivery and pharmacokinetics over conventional approaches.³⁸ Intranasal delivery of polymer-encapsulated antigen triggers a strong immune response, and the success of vaccination depends on the appropriate type of polymer in combination with the antigen.^{61,62} Similarly, researchers have developed lipid and lipid-based NPs as delivery platforms for mRNAs or siRNAs to enable the synthesis of key viral proteins for vaccination or to inactivate critical viral target genes, respectively.³⁹ The field of therapeutic mRNAs to support vaccination has gained momentum, as well,⁶³ at least in part due to nanotechnology-enabled strategies for cargo delivery. Moreover, the versatility of nanoplateforms as antigen-presenting systems offers great opportunities. Considering the possibility of random viral mutations that may alter the antigen shape, functionalizing nanomaterials with a wide number of molecules at the same time to target the virus, or motifs that are specific for pathogens, will increase the efficiency of vaccines and their ability to prevent viral infection.

Several companies are working on mRNA vaccines encoding SARS-CoV-2 proteins such as the spike protein, encapsulated in nanoliposomes with specific physicochemical properties that are potentially akin to those documented for immunization against certain tumor antigens.⁶⁴ The design of such nanocarriers, which will need to escape recognition by scavenger cells and to be nontoxic and nonimmunogenic, is a challenge that will require substantial time prior to clinical availability.

On March 16, 2020, Moderna, through a partnership with the Vaccine Research Center at the U.S. National Institutes of Health, enrolled the first participants into a Phase I clinical trial testing an mRNA vaccine (mRNA-1273) encapsulated in lipid NPs—a record time of just 63 days following sequence selection (NCT04283461).⁶⁵ The enrollment of the first cohort of participants (18 to 55-year-old healthy subjects) concluded on April 16, 2020.⁶⁶ CureVac and BioNTech (in partnership with Pfizer) are currently working on similar vaccines; Pfizer/BioNTech, in particular, have recently started the recruitment in Phase I/II trials (NCT04368728, NCT04380701). A DNA plasmid vaccine by Inovio Pharmaceuticals (INO-4800) has showed promising results in mice and guinea pigs according to a recent article published in *Nature Communications*⁶⁷ and has entered Phase I testing in humans (NCT04336410).

Another candidate COVID-19 vaccine for Phase I clinical trial is from the University of Oxford and AstraZeneca (NCT04324606).⁶⁸ Around 1110 people will take part in the trial, which started recruitment at the end of April 2020. The vaccine is based on a chimpanzee adenovirus vaccine vector (ChAdOx1) and the SARS-CoV-2 spike protein. Chimpanzee adenoviral vectors against different pathogens have been already tested in thousands of subjects with demonstrated safety. To date, ChAdOx1 has been administered to six rhesus macaques exposed to high doses of SARS-CoV-2. The vaccine was unable to prevent infections, although it reduced the severity of the disease: no signs of virus replication were observed in the lungs, with significantly lower levels of respiratory disease and no lung damage compared to control animals, according to a recent article deposited in *bioRxiv*.⁶⁹ Another adenoviral vector vaccine developed by CanSino Biological Inc. and Beijing Institute of Biotechnology using a genetically engineered replication-defective adenovirus type 5 vector to express the SARS-CoV-2 spike protein (Ad5-nCoV) is currently being tested in Phase I/II trials (NCT04398147, NCT04341389, NCT0431312).

Although vaccines based on novel DNA and mRNA technologies might be promising, there are no such kinds of

vaccines on the market, and it is unknown whether they can be effective in humans. Moderna, for instance, has generated preliminary safety data on different mRNA-based vaccines targeting other respiratory viruses, but their more advanced program (on a cytomegalovirus vaccine) is still in Phase II clinical testing. However, on May 18, Moderna announced that mRNA-1273 elicited antibody titers above the levels observed in convalescent individuals (and therefore considered potentially protective) in all eight initial participants across the 25 and 100 μg dose cohorts of the Phase I trial (NCT04283461).⁷⁰ The company, after having received a fast-track approval from the FDA, is now moving on Phase II trials.

Conversely, strong evidence exists regarding the efficacy of protein-based vaccines such as recombinant-protein, viral-vector, attenuated, or inactivated vaccines across different infectious diseases, with licensed vaccines already existing for all of these platforms.²⁷ All of the aforementioned approaches are currently being explored in the context of SARS-CoV-2.²⁷ An inactivated vaccine developed by the China National Pharmaceutical Group (Sinopharm), in collaboration with the Wuhan Institute of Biological Products, is currently tested in a Phase I/II trial (ChiCTR2000031809), and a second inactivated vaccine (in collaboration with the Beijing Institute of Biological Products) has been currently approved for clinical testing (ChiCTR2000032459). A third aluminum salt (alum) adjuvanted inactivated vaccine, developed by Beijing-based Sinovac Biotech's, was able to provide partial or complete protection in rhesus macaques, according to a recent article published in *Science*,⁷¹ and is currently being tested in Phase I/II trials (NCT04383574, NCT04352608).

Live-attenuated vaccines are intrinsically immunogenic (e.g., due to the presence of viral DNA), but extensive safety tests are required due to the rare possibility of reversion to a pathogenic form able to cause infection. Vaccine candidates based in this application have previously been designed for SARS-CoV with high stability.^{72,73} Recombinant-protein vaccines and inactivated vaccines are safer but might require adjuvants to increase their immunogenicity. In the context of SARS-CoV-2, adjuvants are important for two reasons. First, adjuvants might increase the efficacy of the vaccine, especially in subjects with impaired immunological function, such as the elderly, or in subjects with comorbidities resulting in immune dysfunctions; in these patient cohorts, SARS-CoV-2 has a high lethality rate. Second, adjuvants can reduce the amount of vaccine protein(s) required per dose, which could facilitate scaling-up vaccine production in a reduced time frame.

Beyond alum, which is in fact a nanoscale material⁷⁴ that was developed in the 1920s for the tetanus and diphtheria toxoids,⁷⁵ approval for a new adjuvant did not occur until 1997, with the introduction of the oil-in-water emulsion of squalene oil and polysorbate 80 and sorbitan trioleate surfactants (MF59) in the seasonal influenza vaccine for the elderly.⁷⁶ The use of MF59 was further expanded to pandemic and avian influenza vaccines.⁷⁷ Other adjuvants in licensed vaccines have been approved since 2000, as well: (a) AS03 (used for pandemic and avian influenza vaccines), similar to MF59, but including α -tocopherol as an additional immune stimulant; (b) AF 03 (used for pandemic influenza vaccines), an alternative squalene emulsion containing polyoxyethylene, cetostearyl ether, mannitol, and orbitan oleate;⁷⁸ (c) AS 01 (used for herpes zoster vaccine), a liposome-based vaccine adjuvant system containing two immunostimulants, 3-O-desacyl-4'-monophosphoryl lipid A (MPL, a Toll-like receptor 4 agonist) and saponin QS-21,

which activates the ACT-NLRP3 inflammasome pathway;⁷⁹ and (d) AS04 (used for hepatitis B and human papilloma virus vaccines), which is a combination of MPL and aluminum hydroxide.^{76,80}

In this context, the concept of “nanoimmunity by design” relies on the rational design of distinct physicochemical properties and specific functionalization of nanomaterials intended for fine-tuning their potential effects on the immune system.⁸¹ Nanomaterials have emerged as promising tools for immune modulation, either stimulating or suppressing the immune response. In fighting SARS-CoV-2, these properties may find applications for both prevention and therapy and in the context of vaccine development.

Nanomaterials have emerged as promising tools for immune modulation, either stimulating or suppressing the immune response.

Mounting evidence indicates that nanomaterials such as graphene,⁸² nanodiamonds,⁸³ carbon nanotubes,⁸⁴ and polystyrene particles⁸⁵ bear an intrinsic capacity to activate the immune system, depending on their functionalization.⁸⁶ For instance, graphene oxide functionalized with amino groups (GO-NH₂) induces activation of STAT1/IRF1 interferon signaling in monocytes and T cells, resulting in the production of T cell chemoattractants, and macrophage 1 (M1) 1/T-helper 1 (Th1) polarization of the immune response, with negligible toxicity.⁸² Remarkably, the ability of licensed adjuvants such as AS01 and AS03 to enhance adaptive immunity has been linked to their capacity to boost STAT1/IRF1 interferon signaling.⁸⁷ In addition, recent SARS-CoV and MERS-CoV studies suggest that the development of a Th1-type response is central for controlling infection, which also may be true for SARS-CoV-2.⁸⁸

Several groups and consortia have been screening and characterizing nanomaterials according to their immunomodulatory properties and absence of cytotoxicity.^{56,57,82–84,86} The development of an adjuvant for clinical use is a lengthy process that requires extensive Phase III randomized trials in large and diverse cohorts of subjects, and the process generally requires several years.⁷⁶ Pharmaceutical giants such as GlaxoSmithKline (GSK), which owns the ASs mentioned above and other adjuvant platforms, are engaged in several partnerships to embed their adjuvant systems with SARS-CoV-2-protein-based vaccines. A full-length recombinant SARS-CoV-2 glycoprotein nanoparticle vaccine adjuvanted with the saponin-based Matrix M developed by Novavax is in Phase I clinical testing (NCT04368988).⁸⁹

Although it is unlikely that novel adjuvants would be used in the context of the current pandemic, the SARS-CoV-2 pandemic offers an opportunity to reflect on the potential of nanotechnology for vaccine adjuvant development. In this context, it is critical to stream coherent pipelines covering *in vitro* and *in vivo* experiments specifically to select candidate materials that might be tested for clinical implementation as vaccine adjuvants.⁹⁰

In this view, the status of nanomaterial-based vaccine adjuvants has been reviewed.^{91,92} In particular, immunomodulatory effects induced on the innate immune signaling have been demonstrated.⁹¹ For example, nanomaterials such as GO can elicit an inflammasome sensor (NLRP3)-dependent expression of IL-1 β in macrophages.⁹³ Notably, alum, the most commonly

used adjuvant in human vaccines, induces the release of this cytokine in macrophages through the same NLRP-induced mechanism. These results suggest that nanomaterials such as GO and alum may be useful for medical applications.⁹⁴

Considering that new vaccine development typically requires years to be approved and applied to the general population, there is also an urgent need to study how to improve treatment approaches. According to the first Phase III clinical studies, the antiviral drug Remdesivir, which was recently approved by the FDA for COVID-19 treatment in the United States, seems to be a promising treatment for adults diagnosed with COVID-19. Nano-based strategies have already been applied to enhance the effectiveness of Remdesivir in the context of other emerging viral infections (Nipah virus),⁹⁵ suggesting the suitability of nanotechnology to assist with similar strategies for the treatment of COVID-19 as well as other possible pandemics in the future.⁹⁶

Can Nanotechnology Help to Control the Cytokine Storm? One of the main features of COVID-19 is the triggering of a cytokine storm in the body, also known as cytokine release syndrome (CRS), which results from an excessive immune response and leads to the severe deterioration of patient health.^{25,97,98} This inflammatory storm is one of the major causes of the acute respiratory distress syndrome (ARDS) that is often associated with multiple-organ failure, representing the leading causes of death in critical patients.⁹⁸ In particular, the role of interleukin (IL)-6 has been highlighted in patients requiring assisted ventilation. Ongoing clinical trials are testing drugs that block the receptor of IL-6 (Tocilizumab, an anti-IL-6 receptor antibody, and Sarilumab) or IL-6 itself (Siltuximab).

Whereas a well-regulated cytokine response that is rapidly triggered by the host's innate immunity can serve to prevent and to counteract an infection, an excessive, unbalanced, prolonged immune response can seriously harm the body. Therefore, therapeutic strategies aimed at effectively suppressing the cytokine storm are under investigation. Nanomaterials have been exploited to adjust the immune response to an optimized level, and such properties might be explored to inhibit cytokine releases.⁹⁹ Nanosystems can enhance the specificity/efficiency of immunosuppressant delivery to target immune cells, with consequent reductions in drug dose, drug distribution to nontarget tissues and organs, and possible side effects. In addition, specific nanotools can be designed to evade the immune system and to enhance the solubility of poorly soluble immunosuppressant agents; the potential of finely tuning their surface charge opens possibilities for encapsulation strategies and offers accommodation for a high drug load. All of these mechanisms may also occur simultaneously, enhancing the activity of immunosuppressive agents.

Concerning the role of macrophages in COVID-19, the presence of ACE2-expressing CD68+CD169+ macrophages containing SARS-CoV-2 nucleoprotein antigen and showing an increased release of IL-6 was observed in infected spleen and lymph nodes.¹⁰⁰ Notably, immunohistochemical and immunofluorescence analyses of lymph nodes and spleen tissue from autopsy samples of patients who died from COVID-19 revealed lymphocytic apoptosis. The tissues infected by SARS-CoV-2 also showed an upregulated expression of Fas, suggesting a role for CD169+ macrophages in viral spreading, aberrant inflammation, and activation-induced lymphocyte apoptosis. Moreover, histological examinations of biopsy samples of patients who died from COVID-19 revealed an increased alveolar exudate due to the extended neutrophil and monocyte infiltration in lung capillaries with fibrin deposition, probably leading to

difficulties in gas exchange. Through nanomedicine, we envision therapeutic approaches aimed at targeting specific immune subpopulations to avoid these complications, and different nanomaterials have already been explored for their specific impact on different immune cell subpopulations.^{82,83,86} Octadecylamine-functionalized and dexamethasone-adsorbed nanodiamond promotes anti-inflammatory and proregenerative behavior in human macrophages *in vitro*.¹⁰¹ A low dose of this functionalized nanodiamond also reduced macrophage infiltration and expression of proinflammatory mediators iNOS and tumor necrosis factor (TNF)- α in mice. Overall, these results suggest that nanodiamond particles may be useful as an inherently immunomodulatory platform.

Nanosystems can enhance the specificity/efficiency of immunosuppressant delivery to target immune cells, with consequent reductions in drug dose, drug distribution to nontarget tissues and organs, and possible side effects.

Finally, the indiscriminate systemic suppression of the immune system may increase the susceptibility to sepsis due to underlying secondary bacterial infections that can exacerbate critical conditions in patients, causing death.¹⁰² Risk factors for mortality include acquired bacterial infections by opportunistic organisms and primary pathogens. Using nanocarriers to achieve targeted delivery of immunosuppressive drugs, or the specific and controlled inhibition of only a specific immune cell subpopulation, can play a critical role in limiting such complications.

The fast and complete removal of pro-inflammatory cytokines from the bloodstream has been shown to increase survival significantly in patients with early stage sepsis. Adsorption of cytokines from serum by extracorporeal perfusion through porous carbons is one of the most promising ways for their selective, quick, and complete removal from blood circulation. Hierarchical carbon materials with tuned porosity have shown effective adsorption of many cytokines, including IL-6 and even the largest ones, such as TNF- α .¹⁰³ Based on their demonstrated outstanding performance in removing sepsis-associated pro-inflammatory cytokines from blood, mesoporous carbon adsorbents with hierarchical structure, tuned pore size, and surface chemistry, as well as graphene with open and accessible surfaces¹⁰⁴ have significant potential to quickly remove inflammatory cytokines associated with CRS and to prevent mortality arising from an uncontrolled inflammatory cascade, thereby providing enough time for the defense mechanisms of the human body to fight the virus.

Photodynamic Inactivation of SARS-CoV-2. In addition to drug- and vaccine-based antiviral strategies, photodynamic therapy (PDT) stands as a unique approach to inactivate SARS-CoV-2. Using a light-based method, PDT attacks target cells *via* the excitation of photosensitive agents, called photosensitizers (PSs), with radiation characterized by a wavelength corresponding to its absorption spectrum to generate reactive oxygen species (ROS) in the presence of oxygen, which ultimately results in cell death. Photodynamic therapy is primarily used for the clinical treatment of various oncological disorders.¹⁰⁵ It was not until the 1970s that PDT was first used clinically against viruses,¹⁰⁶ exploiting ROS production to damage virus proteins,

nucleic acids, and—if present—lipids.¹⁰⁷ Even though there are research efforts for PDT-based virotherapies against different viruses, including herpes simplex virus, human papilloma virus, and human immunodeficiency virus,^{106–109} clinical use of PDT is limited due to hydrophobicity of PSs, poor target specificity, and limited tissue penetration ability.

Most PSs are hydrophobic and aggregate in aqueous solutions, affecting their photochemical and photobiological properties.^{106,110} For this reason, Lim *et al.* have proposed a promising approach for photodynamic inactivation of viruses with NPs, developing sodium yttrium fluoride (NaYF₄) upconversion NPs (UCNs) with zinc phthalocyanine PSs grafted onto their surfaces. Unlike most PSs, these UCNs are coated with polyethylenimine (PEI), which render them hydrophilic and easier to manipulate. These UCNs showed antiviral activity against Dengue virus serotype 2 and adenovirus type 5, which were used as models of enveloped and non-enveloped viruses, respectively.¹¹⁰ MXenes^{111,112} are a large family of 2D transition metal carbides, nitrides,¹¹³ and carbonitrides¹¹⁴ that exhibit unique electronic, optical, and catalytic properties. They have the general formula M_{n+1}X_nT_x, where M is an early transition metal (Ti, Zr, V, Mo, *etc.*), X is C and/or N, T_x represents the surface functional groups (= O , OH , F , Cl), and $n = 1\text{--}4$.^{115,116} Some examples include Ti₃C₂T_x, V₂CT_x, and Nb₂CT_x, with over 30 stoichiometric compositions already synthesized with more than 100 predicted. Biocompatible MXenes, such as Ti₃C₂T_x, are hydrophilic and are among the most efficient light-to-heat transforming materials.¹¹⁷ The plasmon resonance extinction maxima of Ti₃C₂T_x is at 780 nm, enabling the use of near-infrared (IR) light for PDT. Several other MXenes have absorption maxima in the IR range and have shown outstanding performance in PDT and theranostic applications.¹¹⁸

Fullerene and graphene are also good candidates for virus inactivation by PDT and have proved to be effective against Semliki Forest virus (SFV), vesicular stomatitis virus (VSV), HSV-1, HIV-1, mosquito iridovirus (MIV), and influenza A virus (IAV), as well as the phage MS2.¹⁰⁷ In addition, several 2D nanomaterials, including graphene-based materials, MXenes, black phosphorus, graphitic carbon nitride, tungsten disulfide, and molybdenum disulfide, have been reported to improve the efficacy of PDT considerably for cancer treatment.^{56,57} Therefore, determining if such nanomaterial-based PDT protocols could be exploited to inactivate SARS-CoV-2 is of great interest.

Biomimetic Engineering of Nanodelivery Systems: Artificial Viruses in the Making. In an effort to engineer the next generation of nanoscale vectors, scientists have moved from using inorganic components aimed at obtaining inert structures to utilizing biological building blocks that are able to convey additional functionalities to the resulting construct. To cope with the complexity of the body and to evade the multiple layers of defense that tissues and organs have, it is critical to rely on the ability of certain materials to interact with, rather than to eschew, the biology of our body. Every NP system conceived to date faces one common fate: whether injected, inhaled, ingested, or absorbed through our epithelia, all will at some point come into contact with the mixture of fluids and organic compounds that comprise the body. Under such conditions, every material reacts in a unique way according to the conditions they individually face (*i.e.*, the tissue or body region they are in), their composition (*i.e.*, organic or inorganic), and their physical properties (*i.e.*, size, shape, surface charge).¹¹⁹ Inorganic NPs can function as globular protein mimics because of their similar

size, charge, shape, and surface features that can be chemically functionalized to resemble proteins. These similarities can be used in biotechnology to control virus pathways or cell receptor interactions with NPs.¹²⁰

Among the many attempts, the legendary accomplishments, and the epic failures, we could list thousands of different NPs, differing from one another thanks to the creative endeavors of their designers. Despite their remarkable differences and researchers' endeavors to make them one of a kind, they all aim to achieve one goal: to deliver in a specific way one particular form of payload, while remaining as unnoticed as possible by the body's defense mechanisms. For everyone who has made an effort to create their own version of such a silver bullet, it has come to mind that nature in its incredible variety had already invented a few ingenious solutions to this problem. In the world of nano-based drug delivery, one entity dominates as the quintessential example of precision, efficiency, and stealth: the virus. Not by chance, these two worlds share many features that span from the physical laws that govern their assembly and stability to the chemical similarities in their overall composition.¹²¹

Historically, the field of nanomedicine and the global endeavor to generate NPs for drug delivery arose from one of the greatest struggles in medicine: gene therapy. At the core of that approach was the idea that viruses could be used as Trojan horses to deliver the correct sequence of the gene into the cells that harbored the mutated copy. In order to identify the virus that offered the best delivery service, a cadre of viral strains and species were tested, adapted, and engineered to fit the aims and hit the targets. It took decades of trial and error, of progressive adjustments, and a few tragic mistakes to identify the viruses that could provide the ideal backbone to develop viral vectors able to ferry genetic cargo into the target cell.¹²² In the midst of that global challenge, nanotechnology offered a safer and more controllable alternative: to generate bespoke structures that could replace viral vectors and do the same job, delivering a payload from the point of injection to the site of action.

Fast forward a few decades, and the promises made by both worlds seem to have finally become reality, with a number of active clinical trials, some clinical success stories, and a few commercial products in the market space. Interestingly, the two worlds seem to have maintained a safe distance so as to avoid any collision or dangerous proximity. Exchange of ideas between the fields of gene therapy and nanomedicine is limited, and the potential for disciplinary growth through knowledge exchange has remained elusive to scientists in both fields.⁵ Many scientists have suggested that nanotechnologists could find inspiration in the mechanisms devised by viruses to elude immune surveillance, to overcome biological barriers, and to deliver their genetic payload with high specificity. Similarly, gene therapists would find high-tech solutions to their scalability and safety issues in looking at the new generations of biomimetic particles being generated.

The principles of biomimicry and bioinspiration have been used to design and to engineer drug-delivery technologies that reproduce or recapitulate biological materials, for what pertains to not only their structure and chemistry but also, more importantly, their functions. In drug delivery, surface recognition and nanoscale interactions between materials and biological entities are key to the success of the delivery strategy, and the use of biological building blocks such as membrane proteins has been proposed as a way to convey targeting and shielding moieties simultaneously.¹²³ One can only hope that

the recent events and global attention that viruses are capturing in the scientific world will spur a renewed interest in finding ways to adapt viral features and mechanisms of action to the world of NPs. Increased focus in this field would be useful to create virus-like NPs able to circulate in the blood system, overcoming the endothelial barrier, and to deliver their therapeutic payload with high efficiency.¹²⁴

Interference with Cellular Uptake, Immobilization, and Inactivation of the Virus Outside of the Host Cell.

Nanomaterials can be synthesized with a high specific surface area of a few hundred square meters per gram. Therefore, dependent on the surface properties, nanomaterials efficiently adsorb biomolecules and form a so-called biomolecular corona. This passive, nontargeted adsorption might be utilized to bind viruses, provided that the selected nanomaterial is relatively biocompatible. Viral surface proteins are often modified by sugar moieties or encompass positively charged amino acid patches that bind to lectins or glycosaminoglycans (GAGs) of heparan sulfate (HS), respectively.³² Robust interactions of virus particles with these host receptors is ensured by multivalent binding, which is likely why single-molecule inhibitors often are not capable of efficiently perturbing this key event but multivalent NPs are superior to block binding of different viruses to the host cell.¹²⁵

Gold NPs capped with mercaptoethanesulfonate are effective inhibitors of HSV type 1 infection as they mimic cell-surface-receptor heparan sulfate and, therefore, competitively bind to the virus. Interestingly, polyvalent sulfated Au NPs inhibit virus binding to the host cell dependent on their size. Nanoparticles of diameters equal to and larger than the virus diameter (in this case, the stomatitis virus) more efficiently inhibit the binding to cells than smaller particles. Most likely, larger NPs efficiently cross-link virions, whereas smaller NPs simply decorate the viral surface.¹²⁶ Papp *et al.* found that gold NPs decorated with SA effectively inhibited the binding of influenza virus to the target cells. In this case, viral recognition *via* its surface protein hemagglutinin of SA on the host cell membrane was a prerequisite for cellular entry.¹²⁷ More recently, Cagno *et al.* reported antiviral NPs (Au and iron oxide core) with long and flexible linkers mimicking HS that strongly bind and inactivate viruses such as respiratory syncytial virus *in vitro* and *in vivo* in a lung infection model and even led to irreversible viral deformation.⁵³ Hence, there is ample evidence that biocompatible, functionalized NPs can act as broad-spectrum antivirals. Notably, the receptor-binding domain of the spike S1 protein of SARS-CoV-2 binds not only to ACE2 but also to heparin¹²⁸ and, thus, might be targeted by similar approaches as outlined above.

There is ample evidence that biocompatible, functionalized nanoparticles can act as broad-spectrum antivirals.

One of the most recent strategies to inhibit viral uptake is based on administration of recombinant ACE2 to inhibit binding competitively *via* the spike S1 protein.²¹ Knowing that multivalency is key to block virus–host interactions reliably, researchers have speculated that a nanostructured carrier could not only improve delivery and cargo stability but also might dramatically enhance binding strength.¹²⁹

Speeding up the Nanomedicine-Based Approaches for COVID-19 by *In Silico* Analysis. Currently, repurposing drug molecules is a key strategy for identifying approved or

investigational drugs outside the scope of the original medical indication that can be used to fight COVID-19.^{130,131} There are various advantages to this strategy, including already-established safety profiles, fast transition to clinical studies, and less investment needed, compared to the process of developing an entirely new drug.^{132,133} Therefore, these advantages have the potential to result in less risky and more rapid returns on investment in the development of repurposed drugs, benefits that are particularly important during pandemics. In addition to rapid diagnosis, making recommendations to physicians about rapid treatment methods can save the lives of many people. Combining *in silico* tools such as molecular docking, molecular dynamics, and computational chemistry with large drug databases provides a great advantage in selecting “possible candidates” from among thousands of pharmaceutically active substances (Figure 3). *In silico* analyses should be supported by




Figure 3. Schematic of how *in silico* analysis can be used to select candidate drug molecules for clinical studies. MD, molecular dynamics.

the literature, expert opinions (pharmacologists and clinicians), and, when possible, preclinical and clinical findings. After selecting the best candidates following *in silico* analyses, detailed *in vitro* and *in vivo* experimentation should be undertaken prior to clinical studies. Recently, various drug-repurposing studies have been published to assist in the global COVID-19 pandemic response.^{134–136} Such studies aim to identify whether already-approved drugs have the capacity to interact with viral proteins or receptors on host cells.

In nanomedicine, computational models have recently garnered attention; such work may help to identify how nanomaterials interact with biological systems and to determine how the efficacy of these nanotherapeutics could be improved. Computational models indicate how NPs are taken up by healthy cells or tumor cells, enabling better predictions regarding the pharmacokinetic and pharmacodynamic properties of these materials.¹³⁴ For example, Lunnoo *et al.* used a coarse-grained molecular dynamics (MD) simulation to observe the internalization pathways of various Au nanostructures (nanospheres, nanocages, nanorods, nanoplates, and nano-hexapods) into an idealized mammalian plasma membrane.¹³⁷ Other studies have simulated how different NPs can target tumor cells and deliver drugs.^{138,139} Therefore, *in silico* approaches that are currently used for drug repurposing, including molecular docking, molecular dynamics, and computational chemistry, constitute valuable tools to aid preclinical and clinical studies of nanomaterials directed for disease treatment. Considering the urgent need for nano-

medicine against the current pandemic, *in silico* analyses may be especially useful in guiding the rational design of new NP formulations required to fight SARS-CoV-2.

NANOTECHNOLOGY TOOLS TO DETECT SARS-CoV-2

Standard procedures for detecting the virus from nasopharyngeal and/or oropharyngeal swabs have been reviewed recently and are primarily based on reverse transcription polymerase chain reaction (RT-PCR).¹⁴⁰ Here, we would like to mention some preliminary ideas on nanotechnology-based assays to monitor the presence of SARS-CoV-2. A simplified test and variants thereof to detect viral proteins (e.g., HIV or influenza virus) without the need for expensive equipment is based on the color change of Au NPs bound to antibodies. Similar to the enzyme-linked immunosorbent assay (ELISA) antibodies coupled to Au NPs will form a tertiary complex with the viral antigen and a capture antibody, thereby leading to the immobilization and agglomeration of NPs, which shifts the color from red to blue.³² Such simple, low-cost procedures could be of value in regions with low-resource medical infrastructure, as found in developing countries. For rapid, on-site detection, the development of graphene-based field-effect transistor (FET) biosensing devices coupled to a specific antibody against SARS-CoV-2 spike protein was recently reported.¹⁴¹ Dual-functional plasmonic biosensors combining the plasmonic photothermal (PPT) effect and localized surface plasmon resonance were also recently developed and could be used as a cost-effective and fast alternative to RT-PCR. Here, Au nanomaterials coupled to complementary DNA sequences are used to sense hybridized cDNAs of SARS-CoV-2.¹⁴²

Nanobiosensors are a valuable alternative to conventional laboratory equipments for clinical and environmental analyses.¹⁴³ Usually, nanobiosensors combine the excellent electrical and optical properties of nanomaterials with biological or synthetic molecules used as receptors to detect selectively any kind of analyte. The detection of whole cells (e.g., cancer cells) using electrocatalytic properties of Au NPs toward hydrogen evolution has been reported.¹⁴⁴ This cell-sensing device is based on the reaction of cell surface proteins with specific antibodies conjugated to Au NPs. The same detection technique can also be applied to the detection of viruses, taking advantages of the known antigens and available antibodies. Recently, as mentioned above, a FET sensor (modified with graphene sheets) that uses a specific antibody against SARS-CoV-2 spike protein was reported to detect SARS-CoV-2 in culture medium (limit of detection, LOD: 1.6×10^1 pfu/mL) and clinical samples (LOD: 2.42×10^2 copies/mL).¹⁴¹

Nanobiosensors are a valuable alternative to conventional laboratory equipments for clinical and environmental analyses.

Researchers have also demonstrated solid-phase isothermal recombinase polymerase amplification (RPA) for the detection of *Citrus tristeza* virus (CTV) for plant disease diagnostics. Gold NPs linked with DNA strands on top of an electrode were used to detect *in situ* amplified CTV (RPA assay for amplification of the P20 gene, 387 bp) using electrochemical impedance spectroscopy (EIS) in a $\text{Fe}(\text{CN})_6^{4-}/\text{Fe}(\text{CN})_6^{3-}$ redox system,

being able to detect $1000 \text{ fg } \mu\text{L}^{-1}$ of nucleic acid quantitatively (Figure 4).¹⁴⁵

Paper/nanomaterial-based sensors,^{146,147} in general, and, particularly, NP-based lateral-flow devices that are observed with the naked eye or operated through a smartphone are now the most reported testing platforms for the analysis of COVID-19-related biomarkers.¹⁴⁸ Nanopaper¹⁴⁷ and nanochannels¹⁴⁹ may also offer cost-efficient alternatives for detection of viruses and related biomarkers. Nanomaterials are already being used in theranostics applications. Although the field of nanomaterial applications in nanotheranostics is still in its infancy,⁵⁵ a thoughtful review of the performance characteristics of known nanomaterials may open new avenues of investigation, even for COVID-19-related applications (for both diagnostic and therapies, including vaccines).

NANOTECHNOLOGY TOOLS TO INACTIVATE SARS-CoV-2 IN DIFFERENT ENVIRONMENTS OUTSIDE THE PATIENT

SARS-CoV is highly stable at room temperature and at 4°C , but it is inactivated by ultraviolet light at 254 nm, highly alkaline or acidic conditions of $\text{pH} > 12$ or $\text{pH} < 3$, respectively, or by brief (e.g., 5 min) heat treatment at 65°C . SARS-CoV-2 is expected to be similarly sensitive.¹⁵⁰ Several human coronaviruses can be inactivated by classical disinfectants, including bleach, ethanol, povidone-iodine, chloroxylenol, chlorheximide, and benzalkonium chloride,¹⁵¹ so we expect similar inactivation with SARS-CoV-2. The virus stability on surfaces depends on the composition of the infected material, with inactivation in < 3 h on printing and tissue paper, in < 2 days on treated wood and cloth, in < 4 days on glass and banknotes, and in < 7 days on stainless steel and plastic.¹⁵² Conversely, active viruses can remain on the outer layer of a surgical mask even after 7 days.¹⁵² The surface and aerosol stability of SARS-CoV-2 is comparable to that of SARS-CoV-1,¹⁵³ with both viruses remaining viable in contaminated aerosols for more than 3 h. Infectious SARS-CoV-1 and SARS-CoV-2 remain viable up to 72 h after inoculation on plastic and stainless steel, whereas both are inactivated on copper in less than 4 or 8 h, respectively, and on cardboards in less than 24 and 8 h, respectively.¹⁵³ Therefore, the stability of both viruses is similar, and we can hypothesize that surface treatments with NPs that proved to be effective for SARS-CoV-1 could possibly also be effective for SARS-CoV-2.

Nanotechnology can offer alternative methods to classical disinfection protocols used in healthcare settings, which typically rely on chemical-based disinfection using hydrogen peroxide stream or metal-ion-coated surfaces, biological-based strategies including probiotics or biosurfactants, or physical strategies such as irradiation with ultraviolet (UV) light. Nanotechnology may offer pathways to the development of self-disinfecting surfaces that would avoid contamination of the healthcare and housekeeping staff.

Nanotechnology may offer pathways to the development of self-disinfecting surfaces that would avoid contamination of the healthcare and housekeeping staff.

The methods proposed here for virus inactivation encompass the use of NPs and nanomaterials known for their intrinsic




Figure 4. Schematic of recombinase polymerase amplification-based *Citrus tristeza* virus detection using gold-nanoparticle-modified DNA strands and electrochemical impedance spectroscopic detection. Reprinted from ref 145. Copyright 2019 American Chemical Society.

antipathogenic properties, such as metal-based NPs and graphene, or for their ability to inactivate viruses, bacteria, fungi, or yeasts either photothermally or *via* photocatalysis-induced ROS generation.

SARS-CoV-2 Inactivation by Nano-Based Tools. Silver, copper, and zinc show intrinsic antimicrobial properties and are already used in medical equipment and in healthcare settings. For instance, Ag is used in wound dressing and in urinary and intravascular catheters. It is advantageous to use NPs composed of these metals rather than bulk materials or the metal ions themselves because NPs release the toxic metal ions slowly and progressively right where the antimicrobial action is needed and because NPs can accumulate within cells without being expelled by specialized efflux pumps. The antimicrobial property of Ag has been used since ancient times for medical applications¹⁵⁴ and more recently in commercial products such as silver zeolites in paints¹⁵⁵ and in food trays¹⁵⁶ as biocide. The antiviral efficiency of Ag NPs has been demonstrated in a variety of viruses, including HIV-1,¹⁵⁷ monkeypox virus,¹⁵⁸ bacteriophages UZ1 and MS2,^{159,160} murine norovirus MNV1,^{159,160} HSV,¹⁶¹ HBV,¹⁶² and, recently, in porcine epidemic diarrhea virus (PEDV).¹⁶³ Antiviral properties of Ag NPs arise from three different mechanisms. First, Ag(0) NPs dissolve and release some toxic Ag(I) forms (including Ag⁺ ions), which could be responsible for their antiviral activity. As a soft metal, Ag shows strong affinity toward sulfur, and therefore, it interacts strongly with thiols from small molecules such as cysteine or glutathione or with sulfhydryl groups in the active sites of many enzymes. Ag(I) may interact with surface proteins of viruses or accumulate in host cells and further interact with thiol-containing enzymes that are involved in virus replication, thus hampering their functions. This hypothesis was proposed by Zodrow *et al.* to explain the antiviral property of Ag NPs for bacteriophage MS2 and by De Gussemme *et al.* in response to MNV-1 exposed to Ag NPs.^{159,164} Moreover, Ag₂S nanoclusters (NCs) with diameters of 2.5 and 4 nm showed effective inhibition of PEDV replication in Vero cells *via* inhibition of the synthesis of viral negative-strand RNA and of virus budding from the cells, but not by preventing their anchorage on cell membranes or their intracellular penetration. Exposing cells to Ag⁺ ions at the same concentration did not inhibit virus replication, which led the authors to conclude that the antiviral property of Ag NCs was independent of the release of Ag(I).¹⁶³ However, the mechanisms by which Ag⁺ ions and Ag NCs enter into cells are different and, consequently, their local distribution and handling within cells would also be different. This difference

could lead to different modes of toxic action for Ag ions and Ag NCs toward the viruses that have infected cells. For instance, Ag NCs may aggregate in intracellular areas where vital steps of the viral cycle are performed, such as protein or genome production or assembly of nucleocapsids before their release into the extracellular space, whereas Ag(I) could aggregate in other areas of the cells or be rapidly eliminated. Second, the antiviral efficiency of Ag NPs would derive from physical interaction of Ag NPs with the surface of viruses, which would impede their docking on host cells and limit their infectivity. This mechanism was demonstrated by Elechiguerra *et al.* for HIV-1 exposed to 1–10 nm Ag NPs¹⁵⁷ and by Orłowski *et al.* for HSV-2 exposed to 13, 33, and 46 nm Ag NPs coated with tannic acid.¹⁶¹ Elechiguerra *et al.* found that the optimal size of Ag NPs was around 10 nm, with larger or smaller NP sizes showing weaker physical interaction with the virus. In contrast, Orłowski *et al.* found that the larger the NP, the more effective its blocking was of virus attachment to host cell. The same mechanism, combined with the release of Ag(I), was also proposed by De Gussemme *et al.* to explain the reduced infectivity of MNV-1 virus when exposed to 11.2 nm biogenic Ag NPs.¹⁵⁹ Finally, this docking of Ag NPs on the surface of viruses could be associated with the local release of ROS from the Ag NP surface, which would damage the envelope and/or membrane of the virus. Ag NPs are already used in wound dressings, catheters and other medical equipment; their use could also be envisaged to confer biocidal properties to paints used in healthcare settings, or to air filters or face masks. Ag NPs loaded on filters show effective antiviral activity against bacteriophage MS2, which drops with dust loading.¹⁶⁵

The antimicrobial activity of Cu has also been known since ancient times,¹⁶⁶ and surfaces containing a significant amount of Cu have demonstrated their efficacy to inactivate viruses. Murray *et al.* showed the efficacy of Cu against poliovirus in 1979.¹⁶⁷ More recently, the efficacy of Cu was demonstrated on the HuCoV-229E coronavirus; the effectiveness of Cu to inactivate other forms of coronaviruses suggests potential similar efficacy against SARS-CoV-2.¹⁶⁸ Whereas HuCoV-229E persists for more than 6 days in an infectious state on smooth surfaces (Teflon, polyvinyl chloride, ceramic tiles, glass, stainless steel), it is inactivated in less than 60 min on brasses containing at least 70% Cu or Cu–Ni alloys containing at least 90% Cu.¹⁶⁸ When incubated on Cu-containing surfaces, the viral genome becomes fragmented, ensuring the irreversibility of inactivation.¹⁶⁸ The proposed inactivation mechanisms include both toxicity toward virions of Cu ions released from the Cu-containing surface and

attack of viral proteins and lipids by ROS generated from Cu reacting with exogenous hydrogen or molecular oxygen through Fenton-like or Haber Weiss reactions.¹⁶⁶ Likewise, both SARS-CoV-1 and SARS-CoV-2 are inactivated on Cu surfaces in less than 4 h, whereas they persist for 48–72 h on plastic and stainless steel and less than 24 h on cardboard.¹⁵³ In this case, the main inactivation mechanism is also proposed to be damage to viral proteins and lipids by Cu ions and ROS, in particular, envelope proteins.¹⁵³ Using Cu brasses or Cu-containing alloys rather than stainless steel would provide effective antimicrobial surfaces (doorknobs, bed rails, *etc.*) in healthcare settings. Supported catalysts composed of Al₂O₃ impregnated with Ag and Cu to form Ag/Al₂O₃ (5% Ag) and Cu/Al₂O₃ (10% Cu) also inactivate SARS-CoV virus in less than 5 and 20 min, respectively, which would be useful for air disinfection.¹⁶⁹

Using Cu brasses or Cu-containing alloys rather than stainless steel would provide effective antimicrobial surfaces (doorknobs, bed rails, *etc.*) in healthcare settings.

Cu and CuO NPs have also been shown to release Cu ions when in contact with live cells.^{170,171} The large surface that NPs develop due to their small size endows them with a reactivity higher than that of their bulk counterpart and would fasten the kinetics of Cu ion release. The use of nanostructured Cu surfaces would further enhance their antimicrobial activity. Moreover, these NPs could inactivate viruses if sprayed on contaminated surfaces or loaded onto textile fabrics to confer antimicrobial properties (masks, blouses, *etc.*). Indeed, CuO-impregnated masks have shown remarkable anti-influenza virus (H1N1 and H9N2) activity under simulated breathing conditions,¹⁷² and the activity of these materials toward SARS-CoV-2 should be investigated. The viral disinfectant properties of Ag NPs and CuO NPs is further enhanced when they are combined with Fe as bimetallic particles, due to coupled redox reactions between the two metals.¹⁷³

In addition to metal NPs, graphene derivatives have also shown promising viral inactivation properties.¹⁷⁴ For example, graphene oxide (GO) sheets and sulfated GO derivatives have been found to be effective against herpes simplex virus type-1 (HSV-1) infections, with viral binding and shielding as the two putative main inhibitory mechanisms.¹⁷⁵ Thermally reduced graphene oxide (rGO) sheets functionalized with biocompatible hyperbranched polyglycerol (hPG) and then sulfated have also been generated as graphene-based heparin biomimetics.^{176–178} Sulfate-rich polymers like heparan sulfate and its equivalent soluble counterpart heparin are widely known as broad antiviral agents,^{179,180} but their use is limited due to their anticoagulant effects. Sulfated rGO-hPG sheets were found to be effective at inhibiting orthopoxvirus and herpesvirus strains, particularly in the early stages of the infection, although they could not prevent cell-to-cell spread. Additional antiviral activity of graphene derivatives has been attributed to the negative surface charges and sharp edges of the individualized sheets, as the electrostatic interactions promote binding with the positively charged virus particles. Negative charges on sharp-edged single-sheet GO and rGO were shown to bind and to suppress the infection of pseudorabies, PEDV, EV71, and H9N2 viruses.^{181,182} This mechanism suggests that potentially similar antiviral effects

could be offered by other negatively charged, sharp-edged 2D nanomaterials such as Ti₃C₂T_x MXene, which has shown promising bacterial inactivation effects against both Gram-positive and Gram-negative species due to similar hypothesized mechanisms.^{118,183}

Graphene derivatives linked to virus-specific antibodies have also been adopted in antiviral platforms based on antibody-mediated binding and sensing mechanisms, which have been shown to capture a number of viral species successfully including rotavirus, avian influenza virus subtypes H5 (AIV H5) and H7 (AIV H7), and influenza virus H1N1.^{184–187}

Photothermal Inactivation of SARS-CoV-2. Another example of the use of noble metals for disinfection is the ability of Ag and Au NPs and nanorods to induce heating when illuminated at optimal wavelength, corresponding to the plasmon resonance condition, in a process called plasmonic photothermal treatment.¹⁸⁸ This property is currently being evaluated by nanomedical researchers as a method for killing cancer cells with Au NPs because Au NPs are considered much less toxic than Ag NPs. By tuning NP size and shape, it is possible to emit intense heat under solar irradiation of Au NPs and to inactivate viruses, as demonstrated by Loeb *et al.* with bacteriophages MS2 and PR772 exposed to Au nanorods and nanocubes or to surfaces coated with such NPs.¹⁸⁹ Close contact between NPs and the pathogen is necessary for the process to be effective, which supposes that NPs adsorb onto their surface. Elsewhere, Nazari *et al.* used femtosecond pulsed laser irradiation on Au nanorods to inactivate murine leukemia virus (MLV).¹⁹⁰ Here, inactivation did not require contact between Au NRs and viruses, and the addition of ROS scavengers did not reduce the inactivation effect, suggesting that neither heat nor ROS generation accounted for the observed effect. The authors propose that the underlying mechanism is plasmon-enhanced shockwave generation, which alters virus membrane and/or surface groups and, therefore, reduces virus binding and fusion with the host cell.¹⁹⁰

Inactivation of SARS-CoV-2 by Photocatalytic Nanoparticles. Photocatalytic NPs offer another possible approach to the inactivation of SARS-CoV-2. The most described NP in this category is titanium dioxide (TiO₂), which shows photocatalytic properties when illuminated under UV light, is considered inert, has low toxicity, and is not susceptible to photocorrosion.¹⁹¹ TiO₂ is currently used in paints and lacquers,¹⁵⁵ in self-cleaning windows, and for water purification.¹⁹² TiO₂-containing paints have also been envisaged for purifying ambient air because photocatalytic TiO₂ successfully removes volatile organic compounds (VOCs) when exposed to UV light. However, recent findings show that VOC disruption is associated with the release of toxins in the air, which questions the prudence of TiO₂-doped paints for air purification purposes.¹⁵⁵ If effective, the use of TiO₂ photocatalysis for SARS-CoV-2 inactivation would be particularly useful for surface decontamination using TiO₂-doped paints, aerosol decontamination using air filtration filters and ventilation systems impregnated with TiO₂ that can be exposed to UV light, and for wastewater treatment.

The underlying mechanism of this photocatalytic process relies on the excitation of an electron from the valence band (VB) of the photocatalytic material to the conduction band (CB) when exposed to UV light, which leaves a positive hole (h⁺) in the VB. The e⁻/h⁺ charge carriers migrate to the surface of the photocatalyst and initiate reactions leading to the production of ROS, including the superoxide anion, hydrogen




Figure 5. Droplets and droplet nuclei as important mechanism for transmission of infection. Liquid droplets containing SARS-CoV-2 virions originating from the respiratory tract of infected patients are emitted into the air and carry other materials including bacterial cells and epithelial cells. They are reduced in size by evaporation to small, dry particles resulting in droplet nuclei.

peroxide, the hydroxyl anion, and hydroxyl radical.¹⁹³ The production of hydroxyl radicals by the oxidation of water molecules on the photocatalysts' surface accounts for their disinfection activity, owing to their capacity to oxidize many organic constituents of microorganisms, such as lipid peroxidation, leading to damage to cell wall and cell membrane, protein alteration, and/or DNA damage.¹⁹³ Bare TiO₂ exposed to UV light is effective against a broad spectrum of Gram-positive and Gram-negative bacteria, including multi-drug-resistant strains but also against some fungi, viruses, and yeasts. As discussed by Bogdan *et al.*, according to some authors, viruses would be more susceptible to inactivation than bacteria.¹⁹⁴ Among viruses, some researchers have found that enveloped viruses would be more protected from photocatalytic inactivation than non-enveloped viruses, whereas other authors reported the opposite.¹⁹⁴ Only one article reported the usefulness of this inactivation strategy for treatment of SARS-CoV, using a photocatalytic titanium apatite filter (PTAF). This filter showed effective inactivation of SARS-CoV when exposed for 6 h to UV light.¹⁹⁵ One could also imagine that photocatalysts coupled to UV light could damage spike proteins and lead to decreased infectious capacity of the virus.

Because TiO₂ shows low solar light activity and a high recombination rate of electron–hole pairs, researchers have developed second-generation photocatalysts in which TiO₂ is used in combination with other components, such as metals. This new generation of photocatalysts shows high efficiency of inactivation of a wide range of bacteria and some viruses. Among them, S-doped and N-doped TiO₂ show photocatalytic properties when exposed to visible light and, therefore, would possibly be effective under interior lightning. The antimicrobial properties of these photocatalysts have been tested with a variety of bacteria, sometimes indicating good disinfection efficiency (for reviews, see refs 192 and 193), but to our knowledge, they have not been tested on viruses. Moreover, depositing some Ag NPs on the surface of TiO₂ NPs increases their antiviral efficiency against MS2 by means of increased production of hydroxyl radicals.¹⁹⁶ A Ag- and Cu-doped TiO₂ nanowire membrane is more active in eliminating bacteriophage MS2 from drinking water than are TiO₂, Ag-TiO₂, or Cu-TiO₂ membranes, both in the dark and when exposed to UV light.

The underlying mechanism is thought to combine both enhanced photoactivity due to the lower band gap of (Ag, Cu)-TiO₂ than that of TiO₂¹⁹⁷ and antimicrobial activity of free Ag and Cu ions released into the treated water.¹⁹⁸ Another strategy to improve the antiviral capability of TiO₂ is by increasing its potential to absorb viruses, which has successfully been achieved by mixing TiO₂ NPs with SiO₂ NPs. Due to the large specific surface area of SiO₂, the mixture of NPs inactivated bacteriophage MS2 more effectively than did TiO₂ alone, in spite of reduced hydroxyl production.¹⁹⁹ Glass slides coated with TiO₂ doped with Pt show slightly better efficiency in inactivating aerosols containing influenza A (H3N2) virus than do surfaces coated with only TiO₂ when irradiated with UV-A,²⁰⁰ owing to their increased oxidizing photocatalytic properties. Finally, as described by Byrnes *et al.*,¹⁹³ new photocatalytic materials that show efficient antibacterial activity have been developed and could be tested for the inactivation of SARS-CoV-2. These new materials include (among others) BiVO₄, CuFeO₂, CuY_xFe_{2-x}O₄, LaFeO₈, CuMn₂O₄, ZnMn₂O₄, BaCr₂O₄, SrCr₂O₄, NiCo₂O₄, CuCo₂O₄, LaCoO₃, and La_{0.9}Sr_{0.1}CoO₃. Importantly, before being used for SARS-CoV-2 inactivation, their nontoxicity should be ensured.

Nanotechnology-Based Solutions to Increase the Efficiency and Safety of Protective Devices. Cryoelectron microscopy (cryo-EM) studies show that SARS-CoV-2 virions are particles near the larger end of the NP size range (70–90 nm).^{21,201} However, when dispersed into the air, the infectious particles exist as functionally larger particles. Initially, liquid droplets containing coronavirus virions originating from the respiratory tract of infected patients are emitted during normal breathing, forced expiration (*e.g.*, coughing and sneezing), or aerosol-generating medical procedures (*e.g.*, intubation and suctioning). Liquid droplets emitted into the air through these mechanisms originate from points throughout the respiratory tract and carry within them virions as well as other materials associated with the airways, including bacterial cells and epithelial cells (Figure 5). Droplets are emitted over a wide size range, and their potential viral burden is a cubic function of particle diameter (Figure 6). Thus, larger droplets have the potential to carry a significantly larger burden of virions according to their size and are substantially more hazardous




Figure 6. Maximum theoretical viral burden *versus* droplet nucleus size (nm).

than small droplets. Once emitted into the air, water from droplets immediately begins to evaporate. Water loss is associated with a rapid decrease in both particle diameter and terminal settling velocity (the equilibrium rate of fall of a particle in still air). The rate of evaporation of the largest droplets ($>150 \mu\text{m}$) is often insufficient to slow their swift descent in air, and they impact on nearby surfaces. However, the rapid water loss and sharp slowing of settling velocity of smaller droplets enables them to avoid a similar fate. Their constituent solid residues are instead drawn together during evaporation and cemented with dried respiratory secretions, and they remain aloft as droplet nuclei. Several epidemiological studies have supported the potential for droplet nuclei to be an important means of transmission for SARS-CoV-2.^{202,203}

Assuming a median virion size of about 100 nm, a droplet nucleus of 1 μm diameter could contain up to 370 randomly packed virions. A similar 10 μm diameter droplet nucleus could contain up to 360,000. In practical terms, however, the size-defining element of a droplet nucleus is determined by the component item with the largest volume, which is often a bacterial cell or an epithelial cell. Thus, droplet nuclei in the 1–10 μm size range and above contain far fewer virions than this theoretical maximum.

Filter media, such as those used in N95 masks and in mechanical ventilation systems, consist of myriad interwoven

fibers through which air is moved. Their purpose is to arrest particles as they move through the matrix. Filters capture particles chiefly by three mechanisms: impaction, interception, and diffusion. Impaction occurs when the momentum of a particle propelled toward a filter fiber prevents the particle from diverging around the fiber along the flow lines of the air stream, causing the particle to collide with the fiber. Impaction is the primary mechanism responsible for removing particles greater than 500 nm in diameter. Interception occurs when a particle diverges around a fiber along the flow lines of the airstream, the distance between the vector of the airstream and the centroid of the particle is smaller than the radius of the particle, and the particle touches the fiber. Interception operates efficiently on particles greater than 200 nm in diameter. Diffusion is the final important mechanism of particle removal, and it is most effective at removing very fine particles less than 200 nm, especially at low flow rates. Particles around 300 nm in diameter are least subject to these three removal mechanisms, and they are considered the “most penetrating” particles for a majority of filter types.²⁰⁴

When virus-laden droplet nuclei are deposited on filter media, they penetrate the filter matrix to different depths depending on their size characteristics: larger particles tend to become impacted or intercepted nearer the surface of the intake-facing side, whereas smaller particles penetrate more deeply into the fibrous matrix. In the case of filtering facepiece masks, cyclical breathing can cause changes in the physical characteristics of particles after they have been deposited. Humid exhaled air causes hygroscopic droplet nuclei to swell, becoming larger than they were when captured on filtration media. This size change

From the standpoint of COVID-19, there are many opportunities for nanotechnology-based solutions to increase the efficiency and safety of air filter and mask devices.

can affect the ability of the filter fibers to retain particles and can lead to redistribution, shedding, or even breakthrough of particles.

From the standpoint of COVID-19, there are many opportunities for nanotechnology-based solutions to increase the efficiency and safety of air filter and mask devices. Some




Figure 7. Scanning electron microscope images of electrospun nanofibers on polypropylene filter fabric (a) and titania-coated electrospun nylon nanofibers (b). Reprinted with permission from ref 206. Copyright 2010 Springer Nature.

specific opportunities include (i) improving particle capture and retention characteristics, particularly, in the 300 nm diameter size range; (ii) reducing the effects of exhaled humid air on particle redistribution; (iii) rapid inactivation of membrane-bound microbes including enveloped viruses upon capture; and (iv) thin, high-efficiency filtration media for personal masks that are able to be reused repeatedly without loss of efficiency (e.g., novel electrospun nanofibers). In this context, recent findings exploring the performance of several fabrics commonly used in cloth masks, alone or in combination, suggest that the combined mechanical and electrostatic effect observed in hybrids enabled enhanced performance with a filtration efficiency >80 and >90% for particle sizes <300 and >300 nm, respectively.²⁰⁵

Electrospinning is a technique that is widely used to produce nanofibers with diameters smaller than a micrometer (typically, ~100 nm). Even a micron-thin layer of nanofibers can capture the smallest droplets containing viruses and bacteria and prevent them from traveling through the mask. TiO₂-coated nanofibers deposited on a filter surface by the electrospinning process can capture submicrometer droplets and destroy the virus upon UV irradiation or under natural sunlight. After a micrometer-thick film of polyamide 11 nanofibers was deposited on polypropylene filter fabric, TiO₂ NPs were directly electrospayed onto the nanofibers.²⁰⁶ Scanning electron microscopy (Figure 7) demonstrated that nanofibers were uniformly coated by TiO₂ NPs without agglomeration. TiO₂-coated filters showed excellent photocatalytic and bactericidal activity and photo-induced hydrophilicity.

EMERGING NANOMATERIALS FOR THE FIGHT OF COVID-19

To prevent SARS-CoV-2 spread, proper PPE is critical for healthcare workers and the general public alike. Moreover, the development of face masks and other protective materials that can not only capture the aerosol droplets but also immobilize and kill the virus would be a major step toward preventing the spreading of COVID-19 and other infectious diseases. New nanomaterials can help to accomplish this function such as loading Ag NPs on these materials because they show effective antiviral activity against bacteriophage MS2 when loaded on filter surfaces.¹⁶⁵

The development of face masks and other protective materials that can not only capture the aerosol droplets but also immobilize and kill the virus would be a major step toward preventing the spreading of COVID-19 and other infectious diseases.

Graphene and Transition Metal Dichalcogenides.

Graphene and layered transition metal dichalcogenides (TMDCs) have attracted enormous attention in the area of biomedical applications for diagnostics, therapeutics, safety/security, and environmental monitoring. Whereas pristine graphene has seen applications in biosensors devices, its derivative GO underwent a wealth of investigation for rapid detection, disinfection of pathogens, and enzyme assays, becoming a platform material for a variety of biomedical applications.^{207–209} A decade ago, studies started to emerge where GO was employed for enzyme activity assays,²¹⁰ with the

aim of using it as a platform material for viral helicase inhibition.²¹¹

Initial studies were performed with hepatitis C virus (HCV) NS3²¹² helicase activity and severe acute respiratory syndrome coronavirus (SARS-CoV).²¹¹ These studies were enabled by the evidence that single-stranded nucleic acids can adhere to the surface of GO through π - π stacking interactions between the hexagonal graphitic units of GO and the nucleotides. Beyond therapeutics and diagnostics, graphene is also being pursued as an “engineering” material to enhance the barrier properties of masks, gloves, and gowns for medics against bacteria and viruses larger than 300 nm.²¹³ Contrastingly, MoS₂ nanosheets could be employed as a novel class of 2D nanocarriers functionalized with a variety of therapeutic and disinfection molecules.²¹⁴ They have demonstrated a loading capacity much higher than that of nanographenes and Au nanomaterials along with excellent physiological stability. Another advantage of several TMDCs is their ability to absorb light efficiently (more so than GO) in the near-IR region, with relatively deep penetrability into tissues and minimal phototoxicity, thus enabling different chemophotothermal treatments.²¹⁵

Beyond therapeutics and diagnostics, graphene is also being pursued as an “engineering” material to enhance the barrier properties of masks, gloves, and gowns for medics against bacteria and viruses larger than 300 nm.

Although 2D materials are mostly known in their planar sheet configuration, they can also form different morphologies such as nanoflowers, offering a very high surface area accessible to the virus. The petals are atomically thin, radiating from a common core and their dimensions can vary from tens of nanometers to about a micron. Atomically thin TMDCs—WSe₂,²¹⁶ WS₂,²¹⁷ MoSe₂,²¹⁸ and MoS₂²¹⁹—have been obtained in this morphology when synthesized from chemical precursors in liquid phase at moderate temperatures (up to 300 °C). The syntheses are scalable, and the fact that they are directly grown and not exfoliated from bulk as 2D nanocrystals has the advantage of controlling the chemistry and crystal phase (from 2H to 1T).

This emerging variability of morphology of TMDCs is now attracting interest due to their high surface areas and edge reactivity. The high density of edges with dangling bonds underscores their ability to be readily functionalized with NPs and molecules. In addition, S and Se termination of the basal plane and edges can be particularly favorable to anchor biologically relevant molecules. Nanoflowers of TMDCs present attracting properties in nanomedicine applications because they could host a large number of molecules and NPs on their edges and thus can develop abilities to detect and to inactivate pathogens, to deliver molecules, and to interfere with cellular functioning.²²⁰ Their stability in air and their availability as free-standing nanomaterials in addition to their strong substrate anchoring make them suitable for use in different environments such as in aerosols, on surfaces, in face masks, *etc.*, to detect and/or to inactivate the virus.

Two-Dimensional Carbides and Nitrides (MXenes).

Among the emerging materials, MXenes are particularly promising for the development of coatings that are capable of

capturing and inactivating viruses for use on face masks and other PPE.

MXenes are hydrophilic and they carry high negative charge (zeta-potential in solution is between -30 and -80 mV). As such, $Ti_3C_2T_x$ MXene has been shown to adsorb amino acids strongly²²¹ and may be able to bind strongly to viral spike proteins and to immobilize the virus, thus deactivating it. It performs analogously to a strong magnet for proteins. Furthermore, MXenes have been shown to be photocatalytically active, meaning that once a virus is adsorbed onto the surface, it will be possible to apply light to degrade the adsorbate simultaneously.^{222–224} MXenes are among the most efficient light-to-heat converters due to their plasmon resonance in the visible or IR range. For example, $Ti_3C_2T_x$ is excited by red light (780 nm plasmon resonance) and can be sterilized using a red/infrared lamp as well as solar light if the virus survives on the contact with the surface. A wide variety of MXenes—including $Ti_3C_2T_x$, $Ta_4C_3T_x$, Nb_2CT_x , and others—are biocompatible.^{225–229} At the same time, some MXenes have shown antibacterial properties, likely due to the combination of their charge transfer ability and hydrophilicity.^{183,230,231} Furthermore, it has been shown that the most common and least expensive titanium carbide MXenes have no negative ecological or toxicological impact on the environment.²³² Nanometer-thin coatings of single-layer MXene flakes on the exposed surfaces are worth exploring. Other new materials, such as metal oxides or metal–organic frameworks, deserve attention and should be explored as antiviral materials, as well, because they are also capable of releasing disinfectants from their pores.

In addition to the known pulmonary findings, it is estimated that 30–40% of hospitalized COVID-19 patients have evidence of kidney injury, and a significant percentage of those patients require renal replacement therapy (RRT) if their kidney function fails outright.²³³ Kidney injury is an important predictor of mortality among those infected with COVID-19. Kidney function is essential to life: healthy kidneys filter the blood of harmful toxins, contribute to bone health, and maintain homeostasis of fluid and electrolytes.

When the kidneys fail, hemodialysis offers a life-sustaining therapy to prevent the buildup of uremic toxins that would otherwise result in death.²³⁴ To perform hemodialysis, the patient's blood is passed through a filtration circuit that contains a semipermeable membrane (“dialyzer”). On the other side of the membrane, a balanced fluid (“dialysate”) travels in the opposite direction to the patient's blood, dragging toxins and excess electrolytes across the membrane from blood into dialysate across their concentration gradients. The filtered blood is returned to the patient and the dialysate, once it passes through the filter, is discarded. Novel efficient sorbents for uremic toxins are critically needed to improve the efficiency of current technology, as well as to enable the development of wearable and portable dialysis technologies that could be critical to the care of COVID-19 patients. MXenes can regenerate dialysate by removing toxins that build up in the setting of kidney failure. Preliminary research demonstrates that Ti_3C_2 MXene is biocompatible and selectively adsorbs urea, a uremic toxin that is otherwise difficult to eliminate from dialysate, due to the presence of narrow slit pores between the negatively charged MXene sheets.²³⁵ Thus, MXenes may be able to address key limitations of current ambulatory dialysis systems by offering efficient urea adsorption, small size, and light weight.²³⁵ Experts have posited that MXenes might be a key technology in revolutionizing RRT delivery.²³⁶

RETHINKING THE FUTURE: ONE HEALTH, CONTAMINATIONS OF KNOWLEDGE, AND NANOTECHNOLOGY

The COVID-19 global emergency is making humans face unprecedented challenges. This new social scenario is necessitating collective thought as to where our actions are interconnected and interdependent, going beyond boundaries and cultural heterogeneity. The common interest, in the name of health as our primary need, must be addressed in the future having in mind the “One Health” concept,²³⁷ relying on evidence that the well-being of humans is strictly interconnected with that of animals and the environment.

To address such a complex challenge, cooperation among diverse researchers with complementary expertise is required. The present challenge should be taken as an incredible opportunity to remind our globalized world that, as shown for other scientific contexts, multi- and interdisciplinary methodology involving transversal disciplines, promoting the exchange of knowledge among countries, and increasing diversity in teams all will be essential to achieve new and critical scientific solutions.²³⁸

In this view, nanotechnology is inherently a field in which scientists with incredible diverse backgrounds have converged in fruitful cooperations for multifaceted problems. Today more than ever before, nanotechnology is needed to lay new foundations toward counteracting the current global public health threat; preparing for possible new challenges, for instance, in infectious diseases; and rethinking a more sustainable future based on science.

AUTHOR INFORMATION

Corresponding Authors

Carsten Weiss – Institute of Biological and Chemical Systems, Biological Information Processing, Karlsruhe Institute of Technology, 76344 Eggenstein-Leopoldshafen, Germany; Email: carsten.weiss@kit.edu

Marie Carriere – Univ. Grenoble Alpes, CEA, CNRS, IRIG, SyMMES-CIBEST, F-38000 Grenoble, France; Email: marie.carriere@cea.fr

Lucia Gemma Delogu – Department of Biomedical Sciences, University of Padua, 35122 Padova, Italy; orcid.org/0000-0002-2329-7260; Email: luciamemma.delogu@unipd.it

Authors

Laura Fusco – Cancer Research Department, Sidra Medicine, Doha, Qatar; Department of Chemical and Pharmaceutical Sciences, University of Trieste, 34127 Trieste, Italy

Ilaria Capua – One Health Center of Excellence, University of Florida, Gainesville, Florida 32611, United States

Jose Angel Regla-Nava – Division of Inflammation Biology, La Jolla Institute for Allergy and Immunology, La Jolla, California 92037, United States

Matteo Pasquali – Department of Chemical & Biomolecular Engineering, Department of Chemistry, and Department of Materials Science and Nanoengineering, Rice University, Houston, Texas 77251, United States; orcid.org/0000-0001-5951-395X

James A. Scott – Dalla Lana School of Public Health, University of Toronto, MST 1R4 Toronto, Ontario, Canada

Flavia Vitale – Department of Neurology, Bioengineering, Physical Medicine & Rehabilitation, Center for Neuroengineering and Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States; Center for Neurotrauma,

Neurodegeneration, and Restoration, Corporal Michael J. Crescenzo Veterans Affairs Medical Center, Philadelphia, Pennsylvania 19104, United States

Mehmet Altay Unal – *Stem Cell Institute, Ankara University, Ankara 06100, Turkey*; orcid.org/0000-0001-8607-5043

Cecilia Mattevi – *Department of Materials, Imperial College London, London SW7 2AZ, United Kingdom*; orcid.org/0000-0003-0005-0633

Davide Bedognetti – *Cancer Research Department, Sidra Medicine, Doha, Qatar*

Arben Merkoçi – *Nanobioelectronics & Biosensors Group, Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC and BIST, 08193 Bellaterra, Spain; ICREA - Institució Catalana de Recerca i Estudis Avançats, ES-08010 Barcelona, Spain*; orcid.org/0000-0003-2486-8085

Ennio Tasciotti – *Orthopedics and Sports Medicine, Houston Methodist Hospital, Houston, Texas 77030, United States; Department of Plastic Surgery, MD Anderson, Houston, Texas 77230, United States*; orcid.org/0000-0003-1187-3205

Açelya Yilmazer – *Stem Cell Institute and Department of Biomedical Engineering, Faculty of Engineering, Ankara University, Ankara 06100, Turkey*; orcid.org/0000-0003-2712-7450

Yury Gogotsi – *A.J. Drexel Nanomaterials Institute, and Materials Science and Engineering Department, Drexel University, Philadelphia, Pennsylvania 19104, United States*; orcid.org/0000-0001-9423-4032

Francesco Stellacci – *Institute of Materials, Ecole Polytechnique Federale de Lausanne (EPFL), 1015 Lausanne, Switzerland; Interfaculty Bioengineering Institute, Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland*; orcid.org/0000-0003-4635-6080

Complete contact information is available at:
<https://pubs.acs.org/10.1021/acsnano.0c03697>

Author Contributions

#C.W., M.C., and L.F. contributed equally to this work.

Notes

The authors declare no competing financial interest.

Biographies

Carsten Weiss is a Principal Investigator at the Institute of Biological and Chemical Systems at Karlsruhe Institute of Technology (Germany). His primary interest and expertise lies in the area of molecular toxicology, *i.e.*, the interaction of genotoxins and nanomaterials with living systems and the analysis of adverse effects. The group investigates different nanomaterials and groups of chemicals (PAHs, dioxins, mycotoxins, metals, cytostatic drugs, *etc.*) in various cell culture systems, zebrafish, and mice. A special emphasis of his research is on the mechanisms of toxicity relevant for cytotoxicity and inflammation.

Marie Carriere is a Principal Investigator in the Molecular systems and nanomaterials for energy and health laboratory at Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), in Grenoble (France). Her primary research interests are the toxicity and ecotoxicity of nanomaterials, environmental pollutants, and food additives. In this context, her studies are focused on DNA damage and repair, from damage recognition and the development of analytical techniques to detect and to quantify them with the highest sensitivity and selectivity, to genotoxicity assessment. A multidisciplinary approach is used, going from classical toxicity testing to medium-scale and high-content analysis and -omics approaches coupled with state-of-the-art microscopies and analytical techniques, including synchrotron-based methods

and characterization of the physico-chemistry and fate of nanomaterials.

Laura Fusco received her B.Sc. in Medical Biotechnologies from the University of Milan (Italy) studying the effects of airborne particulate matter on human health. After receiving her M.Sc. in Medical Biotechnologies and Molecular Medicine from the University of Trieste (Italy), in 2018, she earned her Ph.D. in Chemistry from the same university (Prof. Maurizio Prato), with a project on the toxicological effects of graphene and graphene-based materials at the skin level, supported by the European Union H2020 Programme, integrating her research at the Karolinska Institutet (Prof. Bengt Fadeel), Sweden. Currently, she is Visiting Scientist at Sidra Medicine (Qatar) in the framework of the CARBOIMMAP H2020-MSCA-RISE project (L.G. Delogu coordinator) concerning the immune interactions of carbon nanomaterials. In the context of COVID-19, she studies the potential antiviral properties of various nanomaterials as well as the role of airborne particulate matter on the outbreak.

Ilaria Capua is Full Professor and Director of the One Health Center of Excellence at the University of Florida (United States). She is a virologist, known the world over for her ground-breaking research on influenza viruses, particularly avian influenza and for pioneering the open access concept in Science. She also was a Member of the Italian Parliament for over three years (2013–2016). She has authored over 220 scientific publications in peer-reviewed journals and has published scientific books on Avian Influenza and Newcastle disease as well as four books for the general public. She has obtained several awards including the Penn Vet World Leadership in Animal Health Award. She is active in the field of science communication and in promoting female leadership in the scientific arena. She regularly contributes columns and editorials to mainstream Italian press. Her research interests are related to the study of new approaches in infection disease in animals and humans.

Jose Angel Regla-Nava is a Postdoctoral Fellow at the La Jolla Institute, San Diego (United States). His research projects are mainly focused on the Dengue and Zika viruses. He graduated from Universidad de Guadalajara (Mexico) with a B.Sc. degree in Chemistry Pharmaceutical and Biology. He then obtained his M.Sc. in Molecular and Cellular Biology in 2010 and a Ph.D. in Biochemistry, Molecular Biology, Biomedicine, and Biotechnology (Molecular Bioscience) in 2015 from the Universidad Autonoma de Madrid, Spain. His Ph.D. work focused on the study of the identification of the Mechanisms Causing Reversion to Virulence in an Attenuated SARS-CoV for the Design of a Genetically Stable Vaccine.

Matteo Pasquali is the A. J. Hartsook Professor of Chemical & Biomolecular Engineering, Chemistry, and Materials Science & NanoEngineering at Rice University, where he also serves as Chair of the Chemistry Department, Houston (United States). He has been recognized by numerous awards in the field and also founded two companies, DexMat (smart carbon nanotube, CNT, materials) and NanoLinea (medical applications of CNT fibers). His laboratory is a key center for the scalable manufacturing and application of carbon nanotubes and graphene-based materials with enhanced mechanical, electrical and thermal properties. His research targets applications in wearables, energy transmission and harvesting, biomedicine, aerospace, and defense.

James A. Scott is Full Professor the Department of Public Health Sciences and the Gage Occupational & Environmental Health Unit and the Director of the UAMH Centre for Global Microfungal Biodiversity, a world-class repository of medically and environmentally important, living microfungi, Toronto (Canada). Dr. Scott also co-leads SyMBIOTA, a large, CIHR-funded, multidisciplinary team studying

the impact of perinatal environmental exposures on early life atopy and asthma in response to perturbations of the developing human gut microbiome. He also leads an Alfred P. Sloan Foundation project on microbiology of the built environment. His research bridges occupational health and environmental health, focusing on the measurement of exposure to health-relevant biological contaminants, particularly, bioaerosols.

Flavia Vitale is an Assistant Professor in the Department of Neurology, Bioengineering and Physical Medicine and Rehabilitation at the University of Pennsylvania (United States). She received her Ph.D. in Chemical Engineering at the Università di Roma “La Sapienza” (Italy), then completed her training in the Department of Chemical and Biomolecular Engineering at Rice University (United States) in 2015, where she was a R. A. Welch Foundation Postdoctoral Fellow. Dr. Vitale has received a number of awards, including the Graduate Research Fellowship, University of Rome “La Sapienza”, the Taking Flight Award from CURE and the McCabe Fellow Award. Dr. Vitale research focuses on application of carbon nanostructures and MXenes to bioelectronic interfaces and biosensors.

Mehmet Altay Unal received his bachelor degree (2003) and M.S. (2006) from Ankara University Physics Engineering, Turkey, and Ph.D. (2016) degrees from the Ankara University Biotechnology Institute. He worked at the Department of Biomedical Engineering of Florida Institute of Technology, United States (2014–2015). Between 2011 and 2018, he worked at the Ankara University Department of Physical Engineering as a lecturer. He is currently lecturer at the Stem Cell Institute since March 2018. Dr. Unal’s research mainly focuses on the development of cheap, next-generation biosensor devices, understanding protein dynamics and protein–ligand interaction, and developing new drug molecules. He is leading a drug repurposing project for COVID-19 in Turkey, which aims to screen drugs *in silico*.

Cecilia Mattevi is an Associate Professor and Royal Society University Research Fellow in the Department of Materials at Imperial College London (United Kingdom) since October 2012. Cecilia is a Fellow of the Royal Society of Chemistry, and she has been awarded an ERC-Consolidator Grant 2018 on 3D printing of nanomaterial inks for on-chip applications. Mattevi’s group focuses on the precise synthesis of novel atomically thin 2D materials and their three-dimensional structuring *via* 3D printing in the form of miniaturized devices to address pressing challenges in energy storage, energy conversion, and biomedical applications.

Davide Bedognetti is the Director of the Cancer Research Department at Sidra Medicine (Qatar). Dr. Bedognetti received his M.D. and Ph.D. in Clinical and Experimental Oncology and Hematology from the University of Genoa (Italy). After completing his medical residency in Medical Oncology, he joined the Infectious Disease and Immunogenetics Section (IDIS) of the U.S. National Institutes of Health (NIH), where he completed his postdoctoral fellowship. Dr. Bedognetti’s team employs high-throughput approaches to deconvolute the molecular network of host-tumor interactions, and to understand its relationship with treatment effectiveness.

Arben Merkoçi is ICREA Professor and director of Nanobioelectronics and Biosensors Group at Catalan Institute of Nanoscience and Nanotechnology (ICN2) in Barcelona (Spain). He is interested in the design and application of nanobiosensors based on the use of nanotechnology and nanomaterials for several applications with interest for diagnostics, environment, safety, and security. His team is developing nanobiosensing platforms including paper-based nanobiosensors that, given their efficiency and low cost, are considered to be of special interest for point-of-care diagnostics of various diseases including COVID-19. He is cofounder of two spinoff companies,

GraphenicaLab and PaperDrop Diagnostics, the last one also working on COVID-19 diagnostics with paper-based nanobiosensors.

Ennio Tasciotti founded and directed the Center for Biomimetic Medicine and Musculoskeletal Regeneration as an Associate Professor of Nanomedicine and Orthopedic Surgery at the Institute for Academic Medicine. Subsequently, he served as Director of the Center for Musculoskeletal Regeneration as Full Professor of Regenerative Medicine. He has wide expertise in applied science and translational research and a background in biology, biotechnology, and molecular medicine. His main research interests rely on nanotechnology, drug delivery, tissue engineering, and regenerative medicine. He is particularly interested in the development of new lines of research at the cross field of medicine and nanobiotechnology.

Açelya Yilmazer is an Associate Professor at the Department of Biomedical Engineering at Ankara University (Turkey). In 2012, she obtained her Ph.D. in the Nanomedicine Lab based in the School of Pharmacy, University College London (Prof. K. Kostarelos). Later, she continued her postdoctoral work in the same lab on *in vivo* cell reprogramming. She has extensive experience on *in vitro* and *in vivo* preclinical evaluation of nanomaterials. She has coordinated the genotoxicity related work package of the Graphene Flagera project “G-IMMUNOMICS”. She was selected as the “Best Young Investigator” in Turkey by the Turkish Society of Medical Biology and Genetics in 2013 and given the “Young Scientist Award” by the Turkish Academy of Sciences in 2019. Her research group is focusing on the use of nanomaterials and cell reprogramming technologies in cancer and regenerative medicine. She is currently involved in drug repurposing project for COVID-19 in Turkey, and she is coordinating the workpackage related to preclinical investigation of the screened drugs.

Yury Gogotsi is Distinguished University Professor and Charles T. and Ruth M. Bach Professor of Materials Science and Engineering at Drexel University. He also serves as Director of the A.J. Drexel Nanomaterials Institute. He received his M.S. (1984) and Ph.D. (1986) from Kiev Polytechnic and a D.Sc. degree from the Ukrainian Academy of Sciences in 1995. His research group works on 2D carbides, nanostructured carbons, and other nanomaterials for energy, water, and biomedical applications. He has received numerous national and international awards for his research and has been elected a Fellow of many professional societies, including the World Academy of Ceramics and the European Academy of Sciences. He is an Associate Editor at *ACS Nano*.

Francesco Stellacci is a Full Professor leading the Supramolecular Nanomaterials and interfaces laboratory at the Ecole Polytechnique Federale de Lausanne (EPFL), Lausanne, (Switzerland). He is a materials scientist with a postdoctoral experience in Chemistry at the University of Arizona where he worked with Prof. Joe Perry. He started his academic career as a faculty member at the Massachusetts Institute of Technology and then moved as a full professor at the Ecole Polytechnique Fédérale de Lausanne always in the materials science departments. Stellacci has published more than 100 papers and has more than 15 patent applications. His interests are in solid–liquid interfaces, supramolecular chemistry, and nanotechnology. His group tries to use the tools of supramolecular chemistry to create nanomaterials that have unique properties. The main fields of applications are health and environment.

Lucia Gemma Delogu is an Assistant Professor of Biochemistry at the University of Padua, Italy. She is a biochemist with postdoctoral experience in immunology and material science obtained at the University of Southern California, Los Angeles. She has been the Scientific Coordinator of two interdisciplinary European projects on nanomedicine and immune interactions of nanomaterials. In this field,

she has received several awards, including the “Marie S. Curie Individual Fellow” under Horizon 2020 from the European Commission, the “200 Young Best Talents of Italy 2011” from the Italian Ministry of Youth, and “Bedside to Bench & Back Award” from the National Institutes of Health, United States. She pioneered the use of high-dimensional single cell approaches in the context of carbon-based nanomaterials and proposed the “nanoimmunity-by-design” concept. Her research focuses on the immune interactions of nanomaterials, NPs, and air pollution particulate matter. In the context of COVID-19, she studies the potential antiviral properties of various nanomaterials, as well as the role of airborne particulate matter on the outbreak.

ACKNOWLEDGMENTS

L.G.D. acknowledges the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie Grant Agreement No. 734381 (CARBO-immapp), and the University of Padua (Italy) DOR-2020. A.Y. is thankful to the Turkish Academy of Sciences (TUBA) for financial support under the young investigator programme. A.M. thanks funding by the CERCA programme/Generalitat de Catalunya and the Severo Ochoa Centres of Excellence programme and by the Spanish Research Agency (AEI, Grant No. SEV-2017-0706) given to ICN2. C.M. would like to acknowledge the award of funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant Agreement No. 819069) and the award of a Royal Society University Research Fellowship (UF160539) by the UK Royal Society. Y.G. was supported by the U.S. National Science Foundation under Grant No. DMR-1740795. M.C. acknowledges the Labex SERENADE funded by the “Investissements d’Avenir” French Government program of the French National Research Agency (Grant No. ANR-11-LABX-0064) through the A*MIDEX project (Grant No. ANR-11-IDEX-0001-02). The authors acknowledge Prof. Sujana Shersta (La Jolla Institute for Allergy and Immunology) for suggestions in writing this manuscript. We thank Biorender software that was used to create the figures. Any opinion, findings, and conclusion or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the National Science Foundation.

REFERENCES

- (1) Lukashev, A. N.; Zamyatnin, A. A. Viral Vectors for Gene Therapy: Current State and Clinical Perspectives. *Biochemistry (Moscow)* **2016**, *81*, 700–708.
- (2) Anderson, W. F.; Blaese, R. M.; Culver, K. The ADA Human Gene Therapy Clinical Protocol: Points to Consider Response with Clinical Protocol, July 6, 1990. *Hum. Gene Ther.* **1990**, *1*, 331–362.
- (3) Walther, W.; Stein, U. Viral Vectors for Gene Transfer. *Drugs* **2000**, *60*, 249–271.
- (4) Kostarelos, K. Nanoscale Nights of COVID-19. *Nat. Nanotechnol.* **2020**, *15*, 343.
- (5) Yin, H.; Kanasty, R. L.; Eltoukhy, A. A.; Vegas, A. J.; Dorkin, J. R.; Anderson, D. G. Non-Viral Vectors for Gene-Based Therapy. *Nat. Rev. Genet.* **2014**, *15*, 541–555.
- (6) Vincent, M.; de Lázaro, I.; Kostarelos, K. Graphene Materials as 2D Non-Viral Gene Transfer Vector Platforms. *Gene Ther.* **2017**, *24*, 123–132.
- (7) Lozano, R.; Naghavi, M.; Foreman, K.; Lim, S.; Shibuya, K.; Aboyans, V.; Abraham, J.; Adair, T.; Aggarwal, R.; Ahn, S. Y.; Alvarado, M.; Anderson, H. R.; Anderson, L. M.; Andrews, K. G.; Atkinson, C.; Baddour, L. M.; Barker-Collo, S.; Bartels, D. H.; Bell, M. L.; Benjamin, E. J.; et al. Global and Regional Mortality from 235 Causes of Death for

20Age Groups in 1990 and 2010: A Systematic Analysis for the Global Burden of Disease Study 2010. *Lancet* **2012**, *380*, 2095–2128.

- (8) Watkins, K. Emerging Infectious Diseases: A Review. *Curr. Emerg. Hosp. Med. Rep.* **2018**, *6*, 86–93.

- (9) The Top 10 Causes of Death. <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death> (accessed 2020-05-03).

- (10) Gorbalenya, A. E.; Baker, S. C.; Baric, R. S.; de Groot, R. J.; Drosten, C.; Gulyaeva, A. A.; Haagmans, B. L.; Lauber, C.; Leontovich, A. M.; Neuman, B. W.; Penzar, D.; Perlman, S.; Poon, L. L. M.; Samborskiy, D. V.; Sidorov, I. A.; Sola, I.; Ziebuhr, J. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The *Species Severe Acute Respiratory Syndrome-Related Coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2*. *Nat. Microbiol.* **2020**, *5*, 536–544.

- (11) WHO report-98, Johns Hopkins University. www.coronavirus.jhu.edu/map.html (accessed 2020-05-19).

- (12) Lovato, A.; de Filippis, C. Clinical Presentation of COVID-19: A Systematic Review Focusing on Upper Airway Symptoms. *Ear Nose Throat J.* **2020**, No. 014556132092076.

- (13) Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; Cheng, Z.; Yu, T.; Xia, J.; Wei, Y.; Wu, W.; Xie, X.; Yin, W.; Li, H.; Liu, M.; Xiao, Y.; et al. Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. *Lancet* **2020**, *395*, 497–506.

- (14) Lauer, S. A.; Grantz, K. H.; Bi, Q.; Jones, F. K.; Zheng, Q.; Meredith, H. R.; Azman, A. S.; Reich, N. G.; Lessler, J. The Incubation Period of Coronavirus Disease 2019 (COVID-19) from Publicly Reported Confirmed Cases: Estimation and Application. *Ann. Intern. Med.* **2020**, *172*, 577.

- (15) Bansal, M. Cardiovascular Disease and COVID-19. *Diabetes Metab. Syndr.* **2020**, *14*, 247–250. Bansal, M. Cardiovascular disease and COVID-19. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews* **2020**, *14* (3), 247–250.

- (16) Rabb, H. Kidney Diseases in the Time of COVID-19: Major Challenges to Patient Care. *J. Clin. Invest.* **2020**, *130*, 2749.

- (17) Seah, I.; Agrawal, R. Can the Coronavirus Disease 2019 (COVID-19) Affect the Eyes? A Review of Coronaviruses and Ocular Implications in Humans and Animals. *Ocul. Immunol. Inflammation* **2020**, *28*, 391–395.

- (18) Wu, Y.; Xu, X.; Chen, Z.; Duan, J.; Hashimoto, K.; Yang, L.; Liu, C.; Yang, C. Nervous System Involvement After Infection with COVID-19 and Other Coronaviruses. *Brain, Behav., Immun.* **2020**, DOI: 10.1016/j.bbi.2020.03.031.

- (19) Zhou, P.; Yang, X. L.; Wang, X. G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H. R.; Zhu, Y.; Li, B.; Huang, C. L.; Chen, H. D.; Chen, J.; Luo, Y.; Guo, H.; Jiang, R. D.; Liu, M. Q.; Chen, Y.; Shen, X. R.; Wang, X.; Zheng, X. S.; et al. A Pneumonia Outbreak Associated with a New Coronavirus of Probable Bat Origin. *Nature* **2020**, *579*, 270–273.

- (20) Shereen, M. A.; Khan, S.; Kazmi, A.; Bashir, N.; Siddique, R. COVID-19 Infection: Origin, Transmission, and Characteristics of Human Coronaviruses. *J. Adv. Res.* **2020**, *24*, 91–98.

- (21) Monteil, V.; Kwon, H.; Prado, P.; Hagelkruys, A.; Wimmer, R. A.; Stahl, M.; Leopoldi, A.; Garreta, E.; Hurtado del Pozo, C.; Prosper, F.; Romero, J. P.; Wirnsberger, G.; Zhang, H.; Slutsky, A. S.; Conder, R.; Montserrat, N.; Mirazimi, A.; Penninger, J. M. Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. *Cell* **2020**, *181*, 905.

- (22) Zhang, H.; Penninger, J. M.; Li, Y.; Zhong, N.; Slutsky, A. S. Angiotensin-Converting Enzyme 2 (ACE2) as a SARS-CoV-2 Receptor: Molecular Mechanisms and Potential Therapeutic Target. *Intensive Care Med.* **2020**, *46*, 586–590.

- (23) Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Krüger, N.; Herrler, T.; Erichsen, S.; Schiergens, T. S.; Herrler, G.; Wu, N.-H.; Nitsche, A.; Müller, M. A.; Drosten, C.; Pöhlmann, S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* **2020**, *181*, 271.

- (24) Wang, Q.; Zhang, Y.; Wu, L.; Niu, S.; Song, C.; Zhang, Z.; Lu, G.; Qiao, C.; Hu, Y.; Yuen, K. Y.; Wang, Q.; Zhou, H.; Yan, J.; Qi, J.

Structural and Functional Basis of SARS-CoV-2 Entry By Using Human ACE2. *Cell* **2020**, *181*, 894.

(25) Hirano, T.; Murakami, M. COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome. *Immunity* **2020**, *52*, 731.

(26) Gordon, D. E.; Jang, G. M.; Bouhaddou, M.; Xu, J.; Obernier, K.; O'Meara, M. J.; Guo, J. Z.; Swaney, D. L.; Tummino, T. A.; Huettnerlein, R.; Kaake, R. M.; Richards, A. L.; Tutuncuoglu, B.; Foussard, H.; Batra, J.; Haas, K.; Modak, M.; Kim, M.; Haas, P.; Polacco, B. J.; et al. A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing. *Nature* **2020**, DOI: 10.1038/s41586-020-2286-9.

(27) Amanat, F.; Krammer, F. SARS-CoV-2 Vaccines: Status Report. *Immunity* **2020**, *52*, 583–589.

(28) Chen, W. H.; Strych, U.; Hotez, P. J.; Bottazzi, M. E. The SARS-CoV-2 Vaccine Pipeline: An Overview. *Curr. Trop. Med. Rep.* **2020**, *1*–4.

(29) Zhou, Y.; Hou, Y.; Shen, J.; Huang, Y.; Martin, W.; Cheng, F. Network-Based Drug Repurposing for Novel Coronavirus 2019-nCoV/SARS-CoV-2. *Cell Discovery* **2020**, *6*, 14.

(30) Sanders, J. M.; Monogue, M. L.; Jodlowski, T. Z.; Cutrell, J. B. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. *JAMA* **2020**, DOI: 10.1001/jama.2020.6019.

(31) Wu, C.; Liu, Y.; Yang, Y.; Zhang, P.; Zhong, W.; Wang, Y.; Wang, Q.; Xu, Y.; Li, M.; Li, X.; Zheng, M.; Chen, L.; Li, H. Analysis of Therapeutic Targets for SARS-CoV-2 and Discovery of Potential Drugs by Computational Methods. *Acta Pharm. Sin. B* **2020**, DOI: 10.1016/j.apsb.2020.02.008.

(32) Yadavalli, T.; Shukla, D. Role of Metal and Metal Oxide Nanoparticles as Diagnostic and Therapeutic Tools for Highly Prevalent Viral Infections. *Nanomedicine* **2017**, *13*, 219–230.

(33) Singh, L.; Kruger, H. G.; Maguire, G. E. M.; Govender, T.; Parboosing, R. The Role of Nanotechnology in the Treatment of Viral Infections. *Ther. Adv. Infect. Dis.* **2017**, *4*, 105–131.

(34) Jackman, J. A.; Lee, J.; Cho, N.-J. Nanomedicine for Infectious Disease Applications: Innovation towards Broad-Spectrum Treatment of Viral Infections. *Small* **2016**, *12*, 1133–1139.

(35) Adesina, S. K.; Akala, E. O. Nanotechnology Approaches for the Delivery of Exogenous siRNA for HIV Therapy. *Mol. Pharmaceutics* **2015**, *12* (12), 4175–4187.

(36) Lukassen, S.; Chua, R. L.; Trefzer, T.; Kahn, N. C.; Schneider, M. A.; Muley, T.; Winter, H.; Meister, M.; Veith, C.; Boots, A. W.; Hennig, B. P.; Kreuter, M.; Conrad, C.; Eils, R. SARS-CoV-2 Receptor ACE2 and TMPRSS2 are Primarily Expressed in Bronchial Transient Secretory Cells. *EMBO J.* **2020**, *39*, e105114.

(37) Ziegler, C. G. K.; Allon, S. J.; Nyquist, S. K.; Mbanjo, I. M.; Miao, V. N.; Tzouanas, C. N.; Cao, Y.; Yousif, A. S.; Bals, J.; Hauser, B. M.; Feldman, J.; Muus, C.; Wadsworth, M. H., II; Kazer, S. W.; Hughes, T. K.; Doran, B.; Gatter, G. J.; Vukovic, M.; Taliaferro, F.; Mead, B. E.; et al. SARS-CoV-2 Receptor ACE2 is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and is Detected in Specific Cell Subsets Across Tissues. *Cell* **2020**, *181*, 1016.

(38) Yu, M.; Wu, J.; Shi, J.; Farokhzad, O. C. Nanotechnology for Protein Delivery: Overview and Perspectives. *J. Controlled Release* **2016**, *240*, 24–37.

(39) Li, B.; Zhang, X.; Dong, Y. Nanoscale Platforms for Messenger RNA Delivery. *WIREs Nanomed. Nanobiotechnol.* **2019**, *11*, No. e1530.

(40) Mammen, M.; Choi, S.-K.; Whitesides, G. M. Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors. *Angew. Chem., Int. Ed.* **1998**, *37*, 2754–2794.

(41) Fasting, C.; Schalley, C. A.; Weber, M.; Seitz, O.; Hecht, S.; Koks, B.; Dermedde, J.; Graf, C.; Knapp, E. W.; Haag, R. Multivalency as a Chemical Organization and Action Principle. *Angew. Chem., Int. Ed.* **2012**, *51*, 10472–10498.

(42) Choppin, P. W.; Scheid, A. The Role of Viral Glycoproteins in Adsorption, Penetration, and Pathogenicity of Viruses. *Clin. Infect. Dis.* **1980**, *2*, 40–61.

(43) Sarrazin, S.; Lamanna, W. C.; Esko, J. D. Heparan Sulfate Proteoglycans. *Cold Spring Harbor Perspect. Biol.* **2011**, *3*, a004952.

(44) Stencel-Baerenwald, J. E.; Reiss, K.; Reiter, D. M.; Stehle, T.; Dermody, T. S. The Sweet Spot: Defining Virus-Sialic Acid Interactions. *Nat. Rev. Microbiol.* **2014**, *12*, 739–749.

(45) Papp, I.; Sieben, C.; Sisson, A. L.; Kostka, J.; Böttcher, C.; Ludwig, K.; Herrmann, A.; Haag, R. Inhibition of Influenza Virus Activity by Multivalent Glycoarchitectures with Matched Sizes. *ChemBioChem* **2011**, *12*, 887–895.

(46) Bhatia, S.; Camacho, L. C.; Haag, R. Pathogen Inhibition by Multivalent Ligand Architectures. *J. Am. Chem. Soc.* **2016**, *138*, 8654–8666.

(47) Rusnati, M.; Vicenzi, E.; Donalizio, M.; Oreste, P.; Landolfo, S.; Lembo, D. Sulfated K5 *Escherichia coli* Polysaccharide Derivatives: A Novel Class of Candidate Antiviral Microbicides. *Pharmacol. Ther.* **2009**, *123*, 310–322.

(48) Tang, S.; Puryear, W. B.; Seifried, B. M.; Dong, X.; Runstadler, J. A.; Ribbeck, K.; Olsen, B. D. Antiviral Agents from Multivalent Presentation of Sialyl Oligosaccharides on Brush Polymers. *ACS Macro Lett.* **2016**, *5* (3), 413–418.

(49) Dey, P.; Bergmann, T.; Cuellar-Camacho, J. L.; Ehrmann, S.; Chowdhury, M. S.; Zhang, M.; Dahmani, I.; Haag, R.; Azab, W. Multivalent Flexible Nanogels Exhibit Broad-Spectrum Antiviral Activity by Blocking Virus Entry. *ACS Nano* **2018**, *12*, 6429–6442.

(50) Baram-Pinto, D.; Shukla, S.; Perkash, N.; Gedanken, A.; Sarid, R. Inhibition of Herpes Simplex Virus Type 1 Infection by Silver Nanoparticles Capped with Mercaptoethane Sulfonate. *Bioconjugate Chem.* **2009**, *20* (8), 1497–1502.

(51) Cheng, H.-W.; Wang, H.-W.; Wong, T.-Y.; Yeh, H.-W.; Chen, Y.-C.; Liu, D.-Z.; Liang, P.-H. Synthesis of S-Linked NeuAc- α (2-6)-di-LacNAc Bearing Liposomes for H1N1 Influenza Virus Inhibition Assays. *Bioorg. Med. Chem.* **2018**, *26*, 2262–2270.

(52) van Dongen, M. J. P.; Kadam, R. U.; Juraszek, J.; Lawson, E.; Brandenburg, B.; Schmitz, F.; Schepens, W. B. G.; Stoops, B.; van Diepen, H. A.; Jongeneelen, M.; Tang, C.; Vermond, J.; van Eijgen-Obregoso Real, A.; Blokland, S.; Garg, D.; Yu, W.; Goutier, W.; Lanckacker, E.; Klap, J. M.; Peeters, D. C. G.; et al. A Small-Molecule Fusion Inhibitor of Influenza Virus is Orally Active in Mice. *Science* **2019**, *363*, eaar6221.

(53) Cagno, V.; Andreozzi, P.; D'Alicarnasso, M.; Jacob Silva, P.; Mueller, M.; Galloux, M.; Le Goffic, R.; Jones, S. T.; Vallino, M.; Hodek, J.; Weber, J.; Sen, S.; Janeček, E.-R.; Bekdemir, A.; Sanavio, B.; Martinelli, C.; Donalizio, M.; Rameix Welti, M.-A.; Eleouet, J.-F.; Han, Y.; et al. Broad-Spectrum Non-Toxic Antiviral Nanoparticles with a Virucidal Inhibition Mechanism. *Nat. Mater.* **2018**, *17*, 195–203.

(54) Jones, S. T.; Cagno, V.; Janeček, M.; Ortiz, D.; Gasilova, N.; Piret, J.; Gasbarri, M.; Constant, D. A.; Han, Y.; Vuković, L.; Král, P.; Kaiser, L.; Huang, S.; Constant, S.; Kirkegaard, K.; Boivin, G.; Stellacci, F.; Tapparel, C. Modified Cyclodextrins as Broad-Spectrum Antivirals. *Sci. Adv.* **2020**, *6*, No. eaax9318.

(55) Wong, X. Y.; Sena-Torralla, A.; Álvarez-Diduk, R.; Muthoosamy, K.; Merkoçi, A. Nanomaterials for Nanotheranostics: Tuning Their Properties According to Disease Needs. *ACS Nano* **2020**, *14*, 2585–2627.

(56) Gazzi, A.; Fusco, L.; Khan, A.; Bedognetti, D.; Zavan, B.; Vitale, F.; Yilmazer, A.; Delogu, L. G. Photodynamic Therapy Based on Graphene and MXene in Cancer Theranostics. *Front. Bioeng. Biotechnol.* **2019**, *7*, 00295.

(57) Fusco, L.; Gazzi, A.; Peng, G.; Shin, Y.; Vranic, S.; Bedognetti, D.; Vitale, F.; Yilmazer, A.; Feng, X.; Fadeel, B.; Casiraghi, C.; Delogu, L. G. Graphene and Other 2D Materials: A Multidisciplinary Analysis To Uncover the Hidden Potential as Cancer Theranostics. *Theranostics* **2020**, *10*, 5435–5488.

(58) Shetty, Y.; Prabhu, P.; Prabhakar, B. Emerging Vistas in Theranostic Medicine. *Int. J. Pharm.* **2019**, *558*, 29–42.

(59) NIH Clinical Trial of Investigational Vaccine for COVID-19 Begins. <https://www.niaid.nih.gov/news-events/nih-clinical-trial-investigational-vaccine-covid-19-begins> (accessed 2020-05-05).

- (60) Draft Landscape of COVID-19 Candidate Vaccines. <https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines> (accessed 2020-05-22).
- (61) Nochi, T.; Yuki, Y.; Takahashi, H.; Sawada, S.-i.; Mejima, M.; Kohda, T.; Harada, N.; Kong, I. G.; Sato, A.; Kataoka, N.; Tokuhara, D.; Kurokawa, S.; Takahashi, Y.; Tsukada, H.; Kozaki, S.; Akiyoshi, K.; Kiyono, H. Nanogel Antigenic Protein-Delivery System for Adjuvant-Free Intranasal Vaccines. *Nat. Mater.* **2010**, *9*, 572–578.
- (62) Keijzer, C.; Slütter, B.; van der Zee, R.; Jiskoot, W.; van Eden, W.; Broere, F. PLGA, PLGA-TMC and TMC-TPP Nanoparticles Differentially Modulate the Outcome of Nasal Vaccination by Inducing Tolerance or Enhancing Humoral Immunity. *PLoS One* **2011**, *6*, No. e26684.
- (63) Dolgin, E. Business: The Billion-Dollar Biotech. *Nature* **2015**, *522*, 26–28.
- (64) Kranz, L. M.; Diken, M.; Haas, H.; Kreiter, S.; Loquai, C.; Reuter, K. C.; Meng, M.; Fritz, D.; Vascotto, F.; Hefesha, H.; Grunwitz, C.; Vormehr, M.; Hüsemann, Y.; Selmi, A.; Kuhn, A. N.; Buck, J.; Derhovanessian, E.; Rae, R.; Attig, S.; Diekmann, J.; et al. Systemic RNA Delivery to Dendritic Cells Exploits Antiviral Defence for Cancer Immunotherapy. *Nature* **2016**, *534*, 396–401.
- (65) Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19). <https://clinicaltrials.gov/ct2/show/NCT04283461?term=NCT04283461&draw=2&rank=1> (accessed 2020-05-05).
- (66) Moderna's Work on a Potential Vaccine Against COVID-19. www.modernatx.com/modernas-work-potential-vaccine-against-covid-19 (accessed 2020-05-03).
- (67) Smith, T. R. F.; Patel, A.; Ramos, S.; Elwood, D.; Zhu, X.; Yan, J.; Gary, E. N.; Walker, S. N.; Schultheis, K.; Purwar, M.; Xu, Z.; Walters, J.; Bhojnagarwala, P.; Yang, M.; Chokkalingam, N.; Pezzoli, P.; Parzych, E.; Reuschel, E. L.; Doan, A.; Ulaszewska, M.; Feldmann, F.; Allen, E. R.; Sharpe, H.; Schulz, J.; Holbrook, M.; Okumura, A.; Meade-White, K.; Pérez-Pérez, L.; Bissett, C.; Gilbride, C.; et al. ChAdOx1 nCoV-19 Vaccination Prevents SARS-CoV-2 Pneumonia in Rhesus Macaques *bioRxiv* **2020**; <https://doi.org/10.1101/2020.05.13.093195>.
- (68) Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) Against Novel Coronavirus. <https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-interim-phase-1-data-its-mrna-vaccine> (accessed 2020-05-22).
- (69) Gao, Q.; Bao, L.; Mao, H.; Wang, L.; Xu, K.; Yang, M.; Li, Y.; Zhu, L.; Wang, N.; Lv, Z.; Gao, H.; Ge, X.; Kan, B.; Hu, Y.; Liu, J.; Cai, F.; Jiang, D.; Yin, Y.; Qin, C.; Li, J.; et al. Development of an Inactivated Vaccine Candidate for SARS-CoV-2. *Science* **2020**, No. eabc1932.
- (70) Jimenez-Guardeño, J. M.; Regla-Nava, J. A.; Nieto-Torres, J. L.; DeDiego, M. L.; Castaño-Rodríguez, C.; Fernandez-Delgado, R.; Perlman, S.; Enjuanes, L. Identification of the Mechanisms Causing Reversion to Virulence in an Attenuated SARS-CoV for the Design of a Genetically Stable Vaccine. *PLoS Pathog.* **2015**, *11*, No. e1005215.
- (71) Regla-Nava, J. J. A.; Nieto-Torres, J. L.; Jimenez-Guardeño, J. M.; Fernandez-Delgado, R.; Fett, C.; Castaño-Rodríguez, C.; Perlman, S.; Enjuanes, L.; DeDiego, M. L. Severe Acute Respiratory Syndrome Coronaviruses with Mutations in the E Protein Are Attenuated and Promising Vaccine Candidates. *J. Virol.* **2015**, *89*, 3870–3887.
- (72) HogenEsch, H.; O'Hagan, D. T.; Fox, C. B. Optimizing the Utilization of Aluminum Adjuvants in Vaccines: You Might Just Get What You Want. *npj Vaccines* **2018**, *3*, 51.
- (73) McKee, A. S.; Marrack, P. Old and New Adjuvants. *Curr. Opin. Immunol.* **2017**, *47*, 44–51.
- (74) Del Giudice, G.; Rappuoli, R.; Didierlaurent, A. M. Correlates of Adjuvanticity: A Review on Adjuvants in Licensed Vaccines. *Semin. Immunol.* **2018**, *39*, 14–21.
- (75) Vaccines with MF59 Adjuvant Expand the Antibody Repertoire To Target Protective Sites of Pandemic Avian H5N1 Influenza Virus. https://www.accessdata.fda.gov/scripts/publications/search_result_record.cfm?id=32160 (accessed 2020-05-22).
- (76) Klucker, M. F.; Dalençon, F.; Probeck, P.; Haensler, J. AF03, an Alternative Squalene Emulsion-Based Vaccine Adjuvant Prepared by a Phase Inversion Temperature Method. *J. Pharm. Sci.* **2012**, *101*, 4490–4500.
- (77) Didierlaurent, A. M.; Laupèze, B.; Di Pasquale, A.; Hergli, N.; Collignon, C.; Garçon, N. Adjuvant System AS01: Helping To Overcome the Challenges of Modern Vaccines. *Expert Rev. Vaccines* **2017**, *16*, 55–63.
- (78) Garçon, N.; Morel, S.; Didierlaurent, A.; Descamps, D.; Wettendorff, M.; Van Mechelen, M. Development of an AS04-Adjuvanted HPV Vaccine with the Adjuvant System Approach. *BioDrugs* **2011**, *25*, 217–226.
- (79) Gazzi, A.; Fusco, L.; Orecchioni, M.; Ferrari, S.; Franzoni, G.; Yan, J. S.; Rieckher, M.; Peng, G.; Lucherelli, M. A.; Vacchi, I. A.; Do Quey Chau, N.; Criado, A.; Istif, A.; Mancino, D.; Dominguez, A.; Eckert, H.; Vazquez, E.; Da Ros, T.; Nicolussi, P.; Palermo, V.; et al. Graphene, Other Carbon Nanomaterials and the Immune System: Toward Nanoimmunity-by-Design. *J. Phys. Mater.* **2020**, DOI: 10.1088/2515-7639/ab9317.
- (80) Orecchioni, M.; Bedognetti, D.; Newman, L.; Fuoco, C.; Spada, F.; Hendrickx, W.; Marincola, F. M.; Sgarrella, F.; Rodrigues, A. F.; Menard-Moyon, C.; Cesareni, G.; Kostarelos, K.; Bianco, A.; Delogu, L. G. Single-Cell Mass Cytometry and Transcriptome Profiling Reveal the Impact of Graphene on Human Immune Cells. *Nat. Commun.* **2017**, *8*, 1109.
- (81) Fusco, L.; Avitabile, E.; Armuzza, V.; Orecchioni, M.; Istif, A.; Bedognetti, D.; Da Ros, T.; Delogu, L. G. Impact of the Surface Functionalization on Nanodiamond Biocompatibility: A Comprehensive View on Human Blood Immune Cells. *Carbon* **2020**, *160*, 390–404.
- (82) Pescatori, M.; Bedognetti, D.; Venturelli, E.; Menard-Moyon, C.; Bernardini, C.; Muresu, E.; Piana, A.; Maida, G.; Manetti, R.; Sgarrella, F.; Bianco, A.; Delogu, L. G. Functionalized Carbon Nanotubes as Immunomodulator Systems. *Biomaterials* **2013**, *34*, 4395–4403.
- (83) Fuchs, A. K.; Syrovets, T.; Haas, K. A.; Loos, C.; Musyanovych, A.; Mailänder, V.; Landfester, K.; Simmet, T. Carboxyl- and Amino-Functionalized Polystyrene Nanoparticles Differentially Affect the Polarization Profile of M1 and M2 Macrophage Subsets. *Biomaterials* **2016**, *85*, 78–87.
- (84) Orecchioni, M.; Bedognetti, D.; Sgarrella, F.; Marincola, F. M.; Bianco, A.; Delogu, L. G. Impact of Carbon Nanotubes and Graphene on Immune Cells. *J. Transl. Med.* **2014**, *12*, 138.
- (85) Burny, W.; Callegaro, A.; Bechtold, V.; Clement, F.; Delhay, S.; Fissette, L.; Janssens, M.; Leroux-Roels, G.; Marchant, A.; van den Berg, R. A.; Garçon, N.; van der Most, R.; Didierlaurent, A. M. ECR-002 Study Group. Different Adjuvants Induce Common Innate Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in Humans. *Front. Immunol.* **2017**, *8*, 943.
- (86) Prompetchara, E.; Ketloy, C.; Palaga, T. Immune Responses in COVID-19 and Potential Vaccines: Lessons Learned from SARS and MERS Epidemic. *Asian Pac. J. Allergy Immunol.* **2020**, *38*, 1–9.
- (87) Novavax To Receive up to \$388 Million Funding from CEPI for COVID-19 Vaccine Development and Manufacturing. <http://ir.novavax.com/news-releases/news-release-details/novavax-receive-388-million-funding-cepi-covid-19-vaccine> (accessed 2020-05-22).
- (88) Knudsen, N. P.; Olsen, A.; Buonsanti, C.; Follmann, F.; Zhang, Y.; Coler, R. N.; Fox, C. B.; Meinke, A.; D'Oro, U.; Casini, D.; Bonci, A.; Billeskov, R.; De Gregorio, E.; Rappuoli, R.; Harandi, A. M.; Andersen, P.; Agger, E. M. Different Human Vaccine Adjuvants Promote Distinct Antigen-Independent Immunological Signatures Tailored to Different Pathogens. *Sci. Rep.* **2016**, *6*, 19570.

- (91) Zhu, M.; Wang, R.; Nie, G. Applications of Nanomaterials as Vaccine Adjuvants. *Hum. Vaccines Immunother.* **2014**, *10*, 2761–2774.
- (92) Sun, B.; Xia, T. Nanomaterial-Based Vaccine Adjuvants. *J. Mater. Chem. B* **2016**, *4*, 5496–5509.
- (93) Ma, J.; Liu, R.; Wang, X.; Liu, Q.; Chen, Y.; Valle, R. P.; Zuo, Y. Y.; Xia, T.; Liu, S. Crucial Role of Lateral Size for Graphene Oxide in Activating Macrophages and Stimulating Pro-Inflammatory Responses in Cells and Animals. *ACS Nano* **2015**, *9*, 10498–10515.
- (94) Fadeel, B.; Bussy, C.; Merino, S.; Vázquez, E.; Flahaut, E.; Mouchet, F.; Evariste, L.; Gauthier, L.; Koivisto, A. J.; Vogel, U.; Martín, C.; Delogu, L. G.; Buerki-Thurnherr, T.; Wick, P.; Beloin-Saint-Pierre, D.; Hirschier, R.; Pelin, M.; Candotto Carniel, F.; Tretsch, M.; Cesca, F.; et al. Safety Assessment of Graphene-Based Materials: Focus on Human Health and the Environment. *ACS Nano* **2018**, *12*, 10582–10620.
- (95) Kerry, R. G.; Malik, S.; Redda, Y. T.; Sahoo, S.; Patra, J. K.; Majhi, S. Nano-Based Approach To Combat Emerging Viral (NIPAH Virus) Infection. *Nanomedicine* **2019**, *18*, 196–220.
- (96) Cojocar, F.-D.; Botezat, D.; Gardikiotis, I.; Uritu, C.-M.; Dodi, G.; Trandafir, L.; Rezus, C.; Rezus, E.; Tamba, B.-I.; Mihai, C.-T. Nanomaterials Designed for Antiviral Drug Delivery Transport across Biological Barriers. *Pharmaceutics* **2020**, *12*, No. 171.
- (97) Mehta, P.; McAuley, D. F.; Brown, M.; Sanchez, E.; Tattersall, R. S.; Manson, J. J. COVID-19: Consider Cytokine Storm Syndromes and Immunosuppression. *Lancet* **2020**, *395*, 1033–1034.
- (98) Yang, Y.; Shen, C.; Li, J.; Yuan, J.; Wei, J.; Huang, F.; Wang, F.; Li, G.; Li, Y.; Xing, L.; Peng, L.; Yang, M.; Cao, M.; Zheng, H.; Wu, W.; Zou, R.; Li, D.; Xu, Z.; Wang, H.; Zhang, M.; et al. Exuberant Elevation of IP-10, MCP-3 and IL-1ra During SARS-CoV-2 Infection Is Associated with Disease Severity and Fatal Outcome. *medRxiv* **2020**, DOI: [10.1101/2020.03.02.20029975](https://doi.org/10.1101/2020.03.02.20029975).
- (99) Al-Lawati, H.; Aliabadi, H. M.; Makhmalzadeh, B. S.; Lavasanifar, A. Nanomedicine for Immunosuppressive Therapy: Achievements in Pre-Clinical and Clinical Research. *Expert Opin. Drug Delivery* **2018**, *15*, 397–418.
- (100) Chen, Y.; Feng, Z.; Diao, B.; Wang, R.; Wang, G.; Wang, C.; Tan, Y.; Liu, L.; Wang, C.; Liu, Y.; Liu, Y.; Yuan, Z.; Ren, L.; Wu, Y. The Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Directly Decimates Human Spleens and Lymph Nodes. *medRxiv* **2020**, DOI: [10.1101/2020.03.27.20045427](https://doi.org/10.1101/2020.03.27.20045427).
- (101) Pentecost, A.; Kim, M. J.; Jeon, S.; Ko, Y. J.; Kwon, I. C.; Gogotsi, Y.; Kim, K.; Spiller, K. L. Immunomodulatory Nanodiamond Aggregate-Based Platform for the Treatment of Rheumatoid Arthritis. *Regen. Biomater.* **2019**, *6*, 163–174.
- (102) Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; Guan, L.; Wei, Y.; Li, H.; Wu, X.; Xu, J.; Tu, S.; Zhang, Y.; Chen, H.; Cao, B. Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study. *Lancet* **2020**, *395*, 1054–1062.
- (103) Presser, V.; Yeon, S. H.; Vakifahmetoglu, C.; Howell, C. A.; Sandeman, S. R.; Colombo, P.; Mikhailovsky, S.; Gogotsi, Y. Hierarchical Porous Carbide-Derived Carbons for the Removal of Cytokines from Blood Plasma. *Adv. Healthcare Mater.* **2012**, *1*, 796–800.
- (104) Sereydych, M.; Haines, B.; Sokolova, V.; Cheung, P.; Meng, F.; Stone, L.; Mikhailovska, L.; Mikhailovsky, S.; Mochalin, V. N.; Gogotsi, Y. Graphene-Based Materials for the Fast Removal of Cytokines from Blood Plasma. *ACS Appl. Bio Mater.* **2018**, *1*, 436–443.
- (105) Agostinis, P.; Berg, K.; Cengel, K. A.; Foster, T. H.; Girotti, A. W.; Gollnick, S. O.; Hahn, S. M.; Hamblin, M. R.; Juzeniene, A.; Kessel, D.; Korbelik, M.; Moan, J.; Mroz, P.; Nowis, D.; Piette, J.; Wilson, B. C.; Golab, J. Photodynamic Therapy of Cancer: An Update. *Ca-Cancer J. Clin.* **2011**, *61*, 250–281.
- (106) Wainwright, M. Local Treatment of Viral Disease Using Photodynamic Therapy. *Int. J. Antimicrob. Agents* **2003**, *21*, 510–520.
- (107) Wiehe, A.; O'Brien, J. M.; Senge, M. O. Trends and Targets in Antiviral Phototherapy. *Photochem. Photobiol. Sci.* **2019**, *18*, 2565–2612.
- (108) Kharkwal, G. B.; Sharma, S. K.; Huang, Y.-Y.; Dai, T.; Hamblin, M. R. Photodynamic Therapy for Infections: Clinical Applications. *Lasers Surg. Med.* **2011**, *43*, 755–767.
- (109) Costa, L.; Faustino, M. A. F.; Neves, M. G. P. M. S.; Cunha, A.; Almeida, A. Photodynamic Inactivation of Mammalian Viruses and Bacteriophages. *Viruses* **2012**, *4*, 1034–1074.
- (110) Lim, M. E.; Lee, Y.-I.; Zhang, Y.; Chu, J. J. H. Photodynamic Inactivation of Viruses Using Upconversion Nanoparticles. *Biomaterials* **2012**, *33*, 1912–1920.
- (111) Naguib, M.; Kurtoglu, M.; Presser, V.; Lu, J.; Niu, J. J.; Heon, M.; Hultman, L.; Gogotsi, Y.; Barsoum, M. W. Two-Dimensional Nanocrystals Produced by Exfoliation of Ti_3AlC_2 . *Adv. Mater.* **2011**, *23*, 4248–4253.
- (112) Naguib, M.; Presser, V.; Lane, N.; Tallman, D.; Gogotsi, Y.; Lu, J.; Hultman, L.; Barsoum, M. W. Synthesis of a New Nanocrystalline Titanium Aluminum Fluoride Phase by Reaction of Ti_2AlC with Hydrofluoric Acid. *RSC Adv.* **2011**, *1*, 1493.
- (113) Urbankowski, P.; Anasori, B.; Makaryan, T.; Er, D.; Kota, S.; Walsh, P. L.; Zhao, M.; Shenoy, V. B.; Barsoum, M. W.; Gogotsi, Y. Synthesis of Two-Dimensional Titanium Nitride TiN (MXene). *Nanoscale* **2016**, *8*, 11385–11391.
- (114) Naguib, M.; Mashtalir, O.; Carle, J.; Presser, V.; Lu, J.; Hultman, L.; Gogotsi, Y.; Barsoum, M. W. Two-Dimensional Transition Metal Carbides. *ACS Nano* **2012**, *6*, 1322–1331.
- (115) Anasori, B.; Lukatskaya, M. R.; Gogotsi, Y. 2D Metal Carbides and Nitrides (MXenes) for Energy Storage. *Nat. Rev. Mater.* **2017**, *2*, 16098.
- (116) Deysher, G.; Shuck, C. E.; Hantanasirisakul, K.; Frey, N. C.; Foucher, A. C.; Maleski, K.; Sarycheva, A.; Shenoy, V. B.; Stach, E. A.; Anasori, B.; Gogotsi, Y. Synthesis of Mo_4VAlC_4MAX Phase and Two-Dimensional Mo_4VC_4MXene with 5 Atomic Layers of Transition Metals. *ACS Nano* **2020**, *14*, 204–217.
- (117) Hantanasirisakul, K.; Gogotsi, Y. Electronic and Optical Properties of 2D Transition Metal Carbides and Nitrides (MXenes). *Adv. Mater.* **2018**, *30*, 1804779.
- (118) Anasori, B.; Gogotsi, Y. *2D Metal Carbides and Nitrides (MXenes) Structure, Properties and Applications*; Springer International, 2019.
- (119) Parodi, A.; Molinaro, R.; Sushnitha, M.; Evangelopoulos, M.; Martinez, J. O.; Arrighetti, N.; Corbo, C.; Tasciotti, E. Bio-Inspired Engineering of Cell- and Virus-Like Nanoparticles for Drug Delivery. *Biomaterials* **2017**, *147*, 155–168.
- (120) Kotov, N. A. Inorganic Nanoparticles as Protein Mimics. *Science* **2010**, *330*, 188.
- (121) Yoo, J.-W.; Irvine, D. J.; Discher, D. E.; Mitragotri, S. Bio-Inspired, Bioengineered and Biomimetic Drug Delivery Carriers. *Nat. Rev. Drug Discovery* **2011**, *10*, 521–535.
- (122) Friedmann, T. A Brief History of Gene Therapy. *Nat. Genet.* **1992**, *2*, 93–98.
- (123) Molinaro, R.; Corbo, C.; Martinez, J. O.; Taraballi, F.; Evangelopoulos, M.; Minardi, S.; Yazdi, I. K.; Zhao, P.; De Rosa, E.; Sherman, M. B.; De Vita, A.; Toledano Furman, N. E.; Wang, X.; Parodi, A.; Tasciotti, E. Biomimetic Proteolipid Vesicles for Targeting Inflamed Tissues. *Nat. Mater.* **2016**, *15*, 1037–1046.
- (124) Czapar, A. E.; Zheng, Y.-R.; Riddell, I. A.; Shukla, S.; Awuah, S. G.; Lippard, S. J.; Steinmetz, N. F. Tobacco Mosaic Virus Delivery of Phenanthriplatin for Cancer Therapy. *ACS Nano* **2016**, *10*, 4119–4126.
- (125) Baram-Pinto, D.; Shukla, S.; Gedanken, A.; Sarid, R. Inhibition of HSV-1 Attachment, Entry, and Cell-to-Cell Spread by Functionalized Multivalent Gold Nanoparticles. *Small* **2010**, *6*, 1044–1050.
- (126) Vonnemann, J.; Sieben, C.; Wolff, C.; Ludwig, K.; Böttcher, C.; Herrmann, A.; Haag, R. Virus Inhibition Induced by Polyvalent Nanoparticles of Different Sizes. *Nanoscale* **2014**, *6*, 2353–2360.
- (127) Papp, I.; Sieben, C.; Ludwig, K.; Roskamp, M.; Böttcher, C.; Schlecht, S.; Herrmann, A.; Haag, R. Inhibition of Influenza Virus Infection by Multivalent Sialic-Acid-Functionalized Gold Nanoparticles. *Small* **2010**, *6*, 2900–2906.

- (128) Mycroft-West, C.; Su, D.; Elli, S.; Guimond, S.; Miller, G.; Turnbull, J.; Yates, E.; Guerrini, M.; Fernig, D.; Lima, M.; Skidmore, M. The 2019 Coronavirus (SARS-CoV-2) Surface Protein (Spike) S1 Receptor Binding Domain Undergoes Conformational Change Upon Heparin Binding. *bioRxiv* **2020**, DOI: 10.1101/2020.02.29.971093.
- (129) Han, Y.; Král, P. Computational Design of ACE2-Based Peptide Inhibitors of SARS-CoV-2. *ACS Nano* **2020**, *14*, 5143–5147.
- (130) Demkow, U. Chapter 11 - Next Generation Sequencing in Pharmacogenomics. In *Clinical Applications for Next-Generation Sequencing*; Demkow, U., Ploski, R., Eds.; Academic Press: Boston, MA, 2016; pp 217–240.
- (131) Roy, A.; Chaguturu, R. Chapter 3 - Holistic Drug Targeting. In *Innovative Approaches in Drug Discovery*; Patwardhan, B., Chaguturu, R., Eds.; Academic Press: Boston, MA, 2017; pp 65–88.
- (132) Pushpakom, S.; Iorio, F.; Eyers, P. A.; Escott, K. J.; Hopper, S.; Wells, A.; Doig, A.; Guilliams, T.; Latimer, J.; McNamee, C.; Norris, A.; Sanseau, P.; Cavalla, D.; Pirmohamed, M. Drug Repurposing: Progress, Challenges and Recommendations. *Nat. Rev. Drug Discovery* **2019**, *18*, 41–58.
- (133) Dudley, J.; Berliocchi, L. *Drug Repositioning Approaches and Applications for Neurotherapeutics*; CRC Press: Boca Raton, FL, 2019.
- (134) Mullard, A. Flooded by the Torrent: The COVID-19 Drug Pipeline. *Lancet* **2020**, *395*, 1245–1246.
- (135) Senanayake, S. L. Drug Repurposing Strategies for COVID-19. *Future Drug Discovery* **2020**, DOI: 10.4155/fdd-2020-0010.
- (136) Riva, L.; Yuan, S.; Yin, X.; Martin-Sancho, L.; Matsunaga, N.; Burgstaller-Muehlbacher, S.; Pache, L.; De Jesus, P. P.; Hull, M. V.; Chang, M.; Chan, J. F.-W.; Cao, J.; Poon, V. K.-M.; Herbert, K.; Nguyen, T.-T.; Pu, Y.; Nguyen, C.; Rubanov, A.; Martinez-Sobrido, L.; Liu, W.-C.; et al. A Large-Scale Drug Repositioning Survey for SARS-CoV-2 Antivirals. *bioRxiv* **2020**, DOI: 10.1101/2020.04.16.044016.
- (137) Lunnoo, T.; Assawakhajornsak, J.; Puangmali, T. *In Silico* Study of Gold Nanoparticle Uptake into a Mammalian Cell: Interplay of Size, Shape, Surface Charge, and Aggregation. *J. Phys. Chem. C* **2019**, *123*, 3801–3810.
- (138) Kunjiappan, S.; Panneerselvam, T.; Govindaraj, S.; Parasuraman, P.; Baskararaj, S.; Sankaranarayanan, M.; Arunachalam, S.; Babkiewicz, E.; Jeyakumar, A.; Lakshmanan, M. Design, *In Silico* Modelling, and Functionality Theory of Novel Folate Receptor Targeted Rutin Encapsulated Folic Acid Conjugated Keratin Nanoparticles for Effective Cancer Treatment. *Anti-Cancer Agents Med. Chem.* **2020**, *19*, 1966–1982.
- (139) Wijeratne, P. A.; Vavourakis, V. A Quantitative *in Silico* Platform for Simulating Cytotoxic and Nanoparticle Drug Delivery to Solid Tumours. *Interface Focus* **2019**, *9*, 20180063.
- (140) Udugama, B.; Kadhiresan, P.; Kozłowski, H. N.; Malekjahani, A.; Osborne, M.; Li, V. Y. C.; Chen, H.; Mubareka, S.; Gubbay, J. B.; Chan, W. C. W. Diagnosing COVID-19: The Disease and Tools for Detection. *ACS Nano* **2020**, *14*, 3822–3835.
- (141) Seo, G.; Lee, G.; Kim, M. J.; Baek, S.-H.; Choi, M.; Ku, K. B.; Lee, C.-S.; Jun, S.; Park, D.; Kim, H. G.; Kim, S.-J.; Lee, J.-O.; Kim, B. T.; Park, E. C.; Kim, S. I. Rapid Detection of COVID-19 Causative Virus (SARS-CoV-2) in Human Nasopharyngeal Swab Specimens Using Field-Effect Transistor-Based Biosensor. *ACS Nano* **2020**, *14*, 5135–5142.
- (142) Qiu, G.; Gai, Z.; Tao, Y.; Schmitt, J.; Kullak-Ublick, G. A.; Wang, J. Dual-Functional Plasmonic Photothermal Biosensors for Highly Accurate Severe Acute Respiratory Syndrome Coronavirus 2 Detection. *ACS Nano* **2020**, *14*, 5268.
- (143) Quesada-González, D.; Merkoçi, A. Nanomaterial-Based Devices for Point-of-Care Diagnostic Applications. *Chem. Soc. Rev.* **2018**, *47*, 4697–4709.
- (144) Maltez-da Costa, M.; de la Escosura-Muñiz, A.; Nogués, C.; Barrios, L.; Ibáñez, E.; Merkoçi, A. Simple Monitoring of Cancer Cells Using Nanoparticles. *Nano Lett.* **2012**, *12*, 4164–4171.
- (145) Khater, M.; Escosura-Muñiz, A. d. l.; Altet, L.; Merkoçi, A. *In Situ* Plant Virus Nucleic Acid Isothermal Amplification Detection on Gold Nanoparticle-Modified Electrodes. *Anal. Chem.* **2019**, *91*, 4790–4796.
- (146) Parolo, C.; Merkoçi, A. Paper-Based Nanobiosensors for Diagnostics. *Chem. Soc. Rev.* **2013**, *42*, 450–457.
- (147) Quesada-González, D.; Merkoçi, A. Nanoparticle-Based Lateral Flow Biosensors. *Biosens. Bioelectron.* **2015**, *73*, 47–63.
- (148) Udugama, B.; Kadhiresan, P.; Kozłowski, H. N.; Malekjahani, A.; Osborne, M.; Li, V. Y. C.; Chen, H.; Mubareka, S.; Gubbay, J. B.; Chan, W. C. W. Diagnosing COVID-19: The Disease and Tools for Detection. *ACS Nano* **2020**, *14*, 3822–3835.
- (149) de la Escosura-Muñiz, A.; Merkoçi, A. Nanochannels Preparation and Application in Biosensing. *ACS Nano* **2012**, *6*, 7556–7583.
- (150) Darnell, M. E. R.; Subbarao, K.; Feinstone, S. M.; Taylor, D. R. Inactivation of the Coronavirus that Induces Severe Acute Respiratory Syndrome, SARS-CoV. *J. Virol. Methods* **2004**, *121*, 85–91.
- (151) Kampf, G.; Todt, D.; Pfaender, S.; Steinmann, E. Persistence of Coronaviruses on Inanimate Surfaces and their Inactivation with Biocidal Agents. *J. Hosp. Infect.* **2020**, *104*, 246–251.
- (152) Chin, A. W. H.; Chu, J. T. S.; Perera, M. R. A.; Hui, K. P. Y.; Yen, H.-L.; Chan, M. C. W.; Peiris, M.; Poon, L. L. M. Stability of SARS-CoV-2 in Different Environmental Conditions. *Lancet Microbe.* **2020**, *1*, e10.
- (153) van Doremalen, N.; Bushmaker, T.; Morris, D. H.; Holbrook, M. G.; Gamble, A.; Williamson, B. N.; Tamin, A.; Harcourt, J. L.; Thornburg, N. J.; Gerber, S. I.; Lloyd-Smith, J. O.; de Wit, E.; Munster, V. J. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. *N. Engl. J. Med.* **2020**, *382*, 1564–1567.
- (154) Sim, W.; Barnard, R. T.; Blaskovich, M. A. T.; Ziora, Z. M. Antimicrobial Silver in Medicinal and Consumer Applications: A Patent Review of the Past Decade (2007–2017). *Antibiotics (Basel, Switz.)* **2018**, *7*, 93.
- (155) Kaiser, P.; Zuin, S.; Wick, P. Is Nanotechnology Revolutionizing the Paint and Lacquer Industry? A Critical Opinion. *Sci. Total Environ.* **2013**, *442*, 282–289.
- (156) Sohal, I. S.; O'Fallon, K. S.; Gaines, P.; Demokritou, P.; Bello, D. Ingested Engineered Nanomaterials: State of Science in Nanotoxicity Testing and Future Research Needs. *Part. Fibre Toxicol.* **2018**, *15*, 29.
- (157) Elechiguerra, J. L.; Burt, J. L.; Morones, J. R.; Camacho-Bragado, A.; Gao, X.; Lara, H. H.; Yacaman, M. J. Interaction of Silver Nanoparticles with HIV-1. *J. Nanobiotechnol.* **2005**, *3*, 6.
- (158) Rogers, J. V.; Parkinson, C. V.; Choi, Y. W.; Speshock, J. L.; Hussain, S. M. A Preliminary Assessment of Silver Nanoparticle Inhibition of Monkeypox Virus Plaque Formation. *Nanoscale Res. Lett.* **2008**, *3*, 129–133.
- (159) De Gussem, B.; Sintubin, L.; Baert, L.; Thibo, E.; Hennebel, T.; Vermeulen, G.; Uyttendaele, M.; Verstraete, W.; Boon, N. Biogenic Silver for Disinfection of Water Contaminated with Viruses. *Appl. Environ. Microbiol.* **2010**, *76*, 1082–1087.
- (160) Park, S.; Ko, Y. S.; Jung, H.; Lee, C.; Woo, K.; Ko, G. Disinfection of Waterborne Viruses Using Silver Nanoparticle-Decorated Silica Hybrid Composites in Water Environments. *Sci. Total Environ.* **2018**, *625*, 477–485.
- (161) Orłowski, P.; Tomaszewska, E.; Gniadek, M.; Baska, P.; Nowakowska, J.; Sokolowska, J.; Nowak, Z.; Donten, M.; Celichowski, G.; Grobelny, J.; Krzyżowska, M. Tannic Acid Modified Silver Nanoparticles Show Antiviral Activity in Herpes Simplex Virus Type 2 Infection. *PLoS One* **2014**, *9*, No. e104113.
- (162) Lu, L.; Sun, R. W.; Chen, R.; Hui, C. K.; Ho, C. M.; Luk, J. M.; Lau, G. K.; Che, C. M. Silver Nanoparticles Inhibit Hepatitis B Virus Replication. *Antiviral Ther.* **2008**, *13*, 253–262.
- (163) Du, T.; Liang, J.; Dong, N.; Lu, J.; Fu, Y.; Fang, L.; Xiao, S.; Han, H. Glutathione-Capped Ag(2)S Nanoclusters Inhibit Coronavirus Proliferation through Blockage of Viral RNA Synthesis and Budding. *ACS Appl. Mater. Interfaces* **2018**, *10*, 4369–4378.
- (164) Zodrow, K.; Brunet, L.; Mahendra, S.; Li, D.; Zhang, A.; Li, Q.; Alvarez, P. J. Polysulfone Ultrafiltration Membranes Impregnated with Silver Nanoparticles Show Improved Biofouling Resistance and Virus Removal. *Water Res.* **2009**, *43*, 715–23.

- (165) Joe, Y. H.; Park, D. H.; Hwang, J. Evaluation of Ag Nanoparticle Coated Air Filter against Aerosolized Virus: Anti-Viral Efficiency with Dust Loading. *J. Hazard. Mater.* **2016**, *301*, 547–553.
- (166) Grass, G.; Rensing, C.; Solioz, M. Metallic Copper as an Antimicrobial Surface. *Appl. Environ. Microbiol.* **2011**, *77*, 1541–1547.
- (167) Murray, J. P.; Laband, S. J. Degradation of Poliovirus by Adsorption on Inorganic Surfaces. *Appl. Environ. Microbiol.* **1979**, *37*, 480–486.
- (168) Warnes, S. L.; Little, Z. R.; Keevil, C. W. Human Coronavirus 229E Remains Infectious on Common Touch Surface Materials. *mBio* **2015**, *6*, 01697.
- (169) Han, Chen, L.; Duan, S. M.; Yang, Q. X.; Yang, M.; Gao, C.; Zhang, B. Y.; He, H.; Dong, X. P. Efficient and Quick Inactivation of SARS Coronavirus and Other Microbes Exposed to the Surfaces of Some Metal Catalysts. *Biomed. Environ. Sci.* **2005**, *18*, 176–180.
- (170) Lıbalova, H.; Costa, P. M.; Olsson, M.; Farcial, L.; Ortelli, S.; Blossi, M.; Topinka, J.; Costa, A. L.; Fadeel, B. Toxicity of Surface-Modified Copper Oxide Nanoparticles in a Mouse Macrophage Cell Line: Interplay of Particles, Surface Coating and Particle Dissolution. *Chemosphere* **2018**, *196*, 482–493.
- (171) Shi, M.; de Mesy Bentley, K. L.; Palui, G.; Mattoussi, H.; Elder, A.; Yang, H. The Roles of Surface Chemistry, Dissolution Rate, and Delivered Dose in the Cytotoxicity of Copper Nanoparticles. *Nanoscale* **2017**, *9*, 4739–4750.
- (172) Borkow, G.; Zhou, S. S.; Page, T.; Gabbay, J. A Novel Anti-Influenza Copper Oxide Containing Respiratory Face Mask. *PLoS One* **2010**, *5*, No. e11295.
- (173) Kim, H. E.; Lee, H. J.; Kim, M. S.; Kim, T.; Lee, H.; Kim, H. H.; Cho, M.; Hong, S. W.; Lee, C. Differential Microbicidal Effects of Bimetallic Iron-Copper Nanoparticles on *Escherichia coli* and MS2 Coliphage. *Environ. Sci. Technol.* **2019**, *53*, 2679–2687.
- (174) Tu, Z.; Guday, G.; Adeli, M.; Haag, R. Multivalent Interactions between 2D Nanomaterials and Biointerfaces. *Adv. Mater.* **2018**, *30*, 1706709.
- (175) Sametband, M.; Kalt, I.; Gedanken, A.; Sarid, R. Herpes Simplex Virus Type-1 Attachment Inhibition by Functionalized Graphene Oxide. *ACS Appl. Mater. Interfaces* **2014**, *6*, 1228–1235.
- (176) Ziem, B.; Azab, W.; Gholami, M. F.; Rabe, J. P.; Osterrieder, N.; Haag, R. Size-Dependent Inhibition of Herpesvirus Cellular Entry by Polyvalent Nanoarchitectures. *Nanoscale* **2017**, *9*, 3774–3783.
- (177) Ziem, B.; Thien, H.; Achazi, K.; Yue, C.; Stern, D.; Silberreis, K.; Gholami, M. F.; Beckert, F.; Gröger, D.; Müllhaupt, R.; Rabe, J. P.; Nitsche, A.; Haag, R. Highly Efficient Multivalent 2D Nanosystems for Inhibition of Orthopoxvirus Particles. *Adv. Healthcare Mater.* **2016**, *5*, 2922–2930.
- (178) Gholami, M. F.; Lauster, D.; Ludwig, K.; Storm, J.; Ziem, B.; Severin, N.; Böttcher, C.; Rabe, J. P.; Herrmann, A.; Adeli, M.; Haag, R. Functionalized Graphene as Extracellular Matrix Mimics: Toward Well-Defined 2D Nanomaterials for Multivalent Virus Interactions. *Adv. Funct. Mater.* **2017**, *27*, 1606477.
- (179) Marks, R. M.; Lu, H.; Sundaresan, R.; Toida, T.; Suzuki, A.; Imanari, T.; Hernaiz, M. J.; Linhardt, R. J. Probing the Interaction of Dengue Virus Envelope Protein with Heparin: Assessment of Glycosaminoglycan-Derived Inhibitors. *J. Med. Chem.* **2001**, *44*, 2178–2187.
- (180) Bugatti, A.; Urbinati, C.; Ravelli, C.; De Clercq, E.; Liekens, S.; Rusnati, M. Heparin-Mimicking Sulfonic Acid Polymers as Multitarget Inhibitors of Human Immunodeficiency Virus Type 1 Tat and gp120 Proteins. *Antimicrob. Agents Chemother.* **2007**, *51*, 2337.
- (181) Ye, S.; Shao, K.; Li, Z.; Guo, N.; Zuo, Y.; Li, Q.; Lu, Z.; Chen, L.; He, Q.; Han, H. Antiviral Activity of Graphene Oxide: How Sharp Edged Structure and Charge Matter. *ACS Appl. Mater. Interfaces* **2015**, *7*, 21571–21579.
- (182) Song, Z.; Wang, X.; Zhu, G.; Nian, Q.; Zhou, H.; Yang, D.; Qin, C.; Tang, R. Virus Capture and Destruction by Label-Free Graphene Oxide for Detection and Disinfection Applications. *Small* **2015**, *11*, 1171–1176.
- (183) Rasool, K.; Helal, M.; Ali, A.; Ren, C. E.; Gogotsi, Y.; Mahmoud, K. A. Antibacterial Activity of Ti₃C₂T_x MXene. *ACS Nano* **2016**, *10*, 3674–3684.
- (184) Jung, H.; Cheon, D. S.; Liu, F.; Lee, K. B.; Seo, T. S. A Graphene Oxide Based Immuno-Biosensor for Pathogen Detection. *Angew. Chem., Int. Ed.* **2010**, *49*, 5708–5711.
- (185) Xie, Z.; Huang, J.; Luo, S.; Xie, Z.; Xie, L.; Liu, J.; Pang, Y.; Deng, X.; Fan, Q. Ultrasensitive Electrochemical Immunoassay for Avian Influenza Subtype H5 Using Nanocomposite. *PLoS One* **2014**, *9*, No. e94685.
- (186) Huang, J.; Xie, Z.; Xie, Z.; Luo, S.; Xie, L.; Huang, L.; Fan, Q.; Zhang, Y.; Wang, S.; Zeng, T. Silver Nanoparticles Coated Graphene Electrochemical Sensor for the Ultrasensitive Analysis of Avian Influenza Virus H7. *Anal. Chim. Acta* **2016**, *913*, 121–127.
- (187) Singh, R.; Hong, S.; Jang, J. Label-Free Detection of Influenza Viruses using a Reduced Graphene Oxide-based Electrochemical Immunosensor Integrated with a Microfluidic Platform. *Sci. Rep.* **2017**, *7*, 42771.
- (188) Govorov, A. O.; Richardson, H. H. Generating Heat with Metal Nanoparticles. *Nano Today* **2007**, *2*, 30–38.
- (189) Loeb, S.; Li, C.; Kim, J. H. Solar Photothermal Disinfection using Broadband-Light Absorbing Gold Nanoparticles and Carbon Black. *Environ. Sci. Technol.* **2018**, *52*, 205–213.
- (190) Nazari, M.; Xi, M.; Lerch, S.; Alizadeh, M. H.; Ettinger, C.; Akiyama, H.; Gillespie, C.; Gummuluru, S.; Erramilli, S.; Reinhard, B. M. Plasmonic Enhancement of Selective Photonic Virus Inactivation. *Sci. Rep.* **2017**, *7*, 11951.
- (191) Maeda, K.; Domen, K. New Non-Oxide Photocatalysts Designed for Overall Water Splitting under Visible Light. *J. Phys. Chem. C* **2007**, *111*, 7851–7861.
- (192) Dunnill, C. W.; Parkin, I. P. Nitrogen-Doped TiO₂ Thin Films: Photocatalytic Applications for Healthcare Environments. *Dalton Transact.* **2011**, *40*, 1635–1640.
- (193) Byrne, J. A.; Dunlop, P. S.; Hamilton, J. W.; Fernandez-Ibanez, P.; Polo-Lopez, I.; Sharma, P. K.; Vennard, A. S. A Review of Heterogeneous Photocatalysis for Water and Surface Disinfection. *Molecules* **2015**, *20*, 5574–5615.
- (194) Bogdan, J.; Zarzyńska, J.; Pławińska-Czarnak, J. Comparison of Infectious Agents Susceptibility to Photocatalytic Effects of Nanosized Titanium and Zinc Oxides: A Practical Approach. *Nanoscale Res. Lett.* **2015**, *10*, 1023.
- (195) Han, W.; Zhang, P.-H.; Cao, W.-C.; Yang, D. L.; Taira, S.; Okamoto, Y.; Arai, J.-I.; Yan, X. The Inactivation Effect of Photocatalytic Titanium Apatite Filter on SARS Virus. *Prog. Biochem. Biophys.* **2004**, *31*, 982–985.
- (196) Liga, M. V.; Bryant, E. L.; Colvin, V. L.; Li, Q. Virus Inactivation by Silver Doped Titanium Dioxide Nanoparticles for Drinking Water Treatment. *Water Res.* **2011**, *45*, 535–544.
- (197) Behnajady, M. A.; Eskandarloo, H. Silver and Copper Co-Impregnated Onto TiO₂-P25 Nanoparticles and its Photocatalytic Activity. *Chem. Eng. J.* **2013**, *228*, 1207–1213.
- (198) Rao, G.; Brastad, K. S.; Zhang, Q.; Robinson, R.; He, Z.; Li, Y. Enhanced Disinfection of *Escherichia coli* and Bacteriophage MS2 in Water Using a Copper and Silver Loaded Titanium Dioxide Nanowire Membrane. *Front. Environ. Sci. Eng.* **2016**, *10*, 11.
- (199) Liga, M. V.; Maguire-Boyle, S. J.; Jafry, H. R.; Barron, A. R.; Li, Q. Silica Decorated TiO₂ for Virus Inactivation in Drinking Water—Simple Synthesis Method and Mechanisms of Enhanced Inactivation Kinetics. *Environ. Sci. Technol.* **2013**, *47*, 6463–6470.
- (200) Kozlova, E. A.; Safatov, A. S.; Kiselev, S. A.; Marchenko, V. Y.; Sergeev, A. A.; Skarnovich, M. O.; Emelyanova, E. K.; Smetannikova, M. A.; Buryak, G. A.; Vorontsov, A. V. Inactivation and Mineralization of Aerosol Deposited Model Pathogenic Microorganisms over TiO₂ and Pt/TiO₂. *Environ. Sci. Technol.* **2010**, *44*, 5121–5126.
- (201) Kim, J.-M.; Chung, Y.-S.; Jo, H. J.; Lee, N.-J.; Kim, M. S.; Woo, S. H.; Park, S.; Kim, J. W.; Kim, H. M.; Han, M.-G. Identification of Coronavirus Isolated from a Patient in Korea with COVID-19. *Osong Public Health Res. Perspect.* **2020**, *11*, 3–7.

- (202) Chan, J. F.-W.; Yuan, S.; Kok, K.-H.; To, K. K.-W.; Chu, H.; Yang, J.; Xing, F.; Liu, J.; Yip, C. C.-Y.; Poon, R. W.-S.; Tsoi, H.-W.; Lo, S. K.-F.; Chan, K.-H.; Poon, V. K.-M.; Chan, W.-M.; Ip, J. D.; Cai, J.-P.; Cheng, V. C.-C.; Chen, H.; Hui, C. K.-M.; et al. A Familial Cluster of Pneumonia Associated with the 2019 Novel Coronavirus Indicating Person-to-Person Transmission: A Study of a Family Cluster. *Lancet* **2020**, *395*, 514–523.
- (203) Lu, J.; Gu, J.; Li, K.; Xu, C.; Su, W.; Lai, Z.; Zhou, D.; Yu, C.; Xu, B.; Yang, Z. COVID-19 Outbreak Associated with Air Conditioning in Restaurant, Guangzhou, China, 2020. *Emerging Infect. Dis.* **2020**, DOI: 10.3201/eid2607.200764.
- (204) Hinds, W. C. *Aerosol Technology: Properties, Behavior, and Measurement of Airborne Particles*, 2nd ed.; Wiley: New York, 1999.
- (205) Konda, A.; Prakash, A.; Moss, G. A.; Schmoltdt, M.; Grant, G. D.; Guha, S. Aerosol Filtration Efficiency of Common Fabrics Used in Respiratory Cloth Masks. *ACS Nano* **2020**, *14*, 6339.
- (206) Lee, B.-Y.; Behler, K.; Kurtoglu, M. E.; Wynosky-Dolfi, M. A.; Rest, R. F.; Gogotsi, Y. Titanium Dioxide-Coated Nanofibers for Advanced Filters. *J. Nanopart. Res.* **2010**, *12*, 2511–2519.
- (207) Stanford, M. G.; Li, J. T.; Chen, Y.; McHugh, E. A.; Liopo, A.; Xiao, H.; Tour, J. M. Self-Sterilizing Laser-Induced Graphene Bacterial Air Filter. *ACS Nano* **2019**, *13*, 11912–11920.
- (208) Tu, Y.; Lv, M.; Xiu, P.; Huynh, T.; Zhang, M.; Castelli, M.; Liu, Z.; Huang, Q.; Fan, C.; Fang, H.; Zhou, R. Destructive Extration of Phospholipids from *Escherichia coli* Membranes by Graphene Nanosheets. *Nat. Nanotechnol.* **2013**, *8*, 594–601.
- (209) Nguyen, A. T.; Huang, Q.-L.; Yang, Z.; Lin, N.; Xu, G.; Liu, X. Y. Silks: Crystal Networks in Silk Fibrous Materials: From Hierarchical Structure to Ultra Performance. *Small* **2015**, *11*, 1013–1013.
- (210) Jang, H.; Kim, Y.-K.; Kwon, H.-M.; Yeo, W.-S.; Kim, D.-E.; Min, D.-H. A Graphene-Based Platform for the Assay of Duplex-DNA Unwinding by Helicase. *Angew. Chem., Int. Ed.* **2010**, *49*, 5703–5707.
- (211) Jang, H. H.; Ryoo, S.-R.; Kim, Y.-K.; Yoon, S.; Kim, H.; Han, S. W.; Choi, B.-S.; Kim, D.-E.; Min, D.-H. Discovery of Hepatitis C Virus NS3 Helicase Inhibitors by a Multiplexed, High-Throughput Helicase Activity Assay Based on Graphene Oxide. *Angew. Chem., Int. Ed.* **2013**, *52*, 2340–2344.
- (212) Leung, K.-H.; He, H.-Z.; He, B.; Zhong, H.-J.; Lin, S.; Wang, Y.-T.; Ma, D.-L.; Leung, C.-H. Label-Free Luminescence Switch-On Detection of Hepatitis C Virus NS3 Helicase Activity Using a G-Quadruplex-Selective Probe. *Chem. Sci.* **2015**, *6*, 2166–2171.
- (213) Guardian G-Volt Masks Would Use Graphene and Electrical Charge To Repel Viruses and Bacteria. www.dezeen.com/2020/03/06/guardian-g-volt-face-mask-graphene-coronavirus-bacteria/ (accessed 2020-05-03).
- (214) Liu, T.; Wang, C.; Gu, X.; Gong, H.; Cheng, L.; Shi, X.; Feng, L.; Sun, B.; Liu, Z. Drug Delivery with PEGylated MoS₂ Nano-sheets for Combined Photothermal and Chemotherapy of Cancer. *Adv. Mater.* **2014**, *26*, 3433–3440.
- (215) Chou, S. S.; Kaehr, B.; Kim, J.; Foley, B. M.; De, M.; Hopkins, P. E.; Huang, J.; Brinker, C. J.; Dravid, V. P. Chemically Exfoliated MoS₂ as Near-Infrared Photothermal Agents. *Angew. Chem., Int. Ed.* **2013**, *52*, 4160–4164.
- (216) Sokolikova, M. S.; Sherrell, P. C.; Palczynski, P.; Bemmer, V. L.; Mattevi, C. Direct Solution-Phase Synthesis of 1T' WSe₂ Nanosheets. *Nat. Commun.* **2019**, *10*, 712.
- (217) Mahler, B.; Hoepfner, V.; Liao, K.; Ozin, G. A. Colloidal Synthesis of 1T-WS₂ and 2H-WS₂ Nanosheets: Applications for Photocatalytic Hydrogen Evolution. *J. Am. Chem. Soc.* **2014**, *136*, 14121–14127.
- (218) Sun, D.; Feng, S.; Terrones, M.; Schaak, R. E. Formation and Interlayer Decoupling of Colloidal MoS₂ Nanoflowers. *Chem. Mater.* **2015**, *27*, 3167–3175.
- (219) Hu, Z.; Wang, L.; Zhang, K.; Wang, J.; Cheng, F.; Tao, Z.; Chen, J. MoS₂ Nanoflowers with Expanded Interlayers as High-Performance Anodes for Sodium-Ion Batteries. *Angew. Chem., Int. Ed.* **2014**, *53*, 12794–12798.
- (220) Jing, X.; Zhi, Z.; Wang, D.; Liu, J.; Shao, Y.; Meng, L. Multifunctional Nanoflowers for Simultaneous Multimodal Imaging and High-Sensitivity Chemo-Photothermal Treatment. *Bioconjugate Chem.* **2018**, *29*, 559–570.
- (221) Chen, C.; Boota, M.; Urbankowski, P.; Anasori, B.; Miao, L.; Jiang, J.; Gogotsi, Y. Effect of Glycine Functionalization of 2D Titanium Carbide (MXene) on Charge Storage. *J. Mater. Chem. A* **2018**, *6*, 4617–4622.
- (222) Nguyen, V.-H.; Nguyen, B.-S.; Hu, C.; Nguyen, C. C.; Nguyen, D. L. T.; Nguyen Dinh, M. T.; Vo, D.-V. N.; Trinh, Q. T.; Shokouhimehr, M.; Hasani, A.; Kim, S. Y.; Le, Q. V. Novel Architecture Titanium Carbide (Ti₃C₂T_x) MXene Cocatalysts toward Photocatalytic Hydrogen Production: A Mini-Review. *Nanomaterials* **2020**, *10*, 602.
- (223) Wong, Z. M.; Tan, T. L.; Yang, S.-W.; Xu, G. Q. Enhancing the Photocatalytic Performance of MXenes via Stoichiometry Engineering of Their Electronic and Optical Properties. *ACS Appl. Mater. Interfaces* **2018**, *10*, 39879–39889.
- (224) Low, J.; Zhang, L.; Tong, T.; Shen, B.; Yu, J. TiO₂/MXene Ti₃C₂ Composite with Excellent Photocatalytic CO₂ Reduction Activity. *J. Catal.* **2018**, *361*, 255–266.
- (225) Huang, K.; Li, Z.; Lin, J.; Han, G.; Huang, P. Two-Dimensional Transition Metal Carbides and Nitrides (MXenes) for Biomedical Applications. *Chem. Soc. Rev.* **2018**, *47*, 5109–5124.
- (226) Dai, C.; Chen, Y.; Jing, X.; Xiang, L.; Yang, D.; Lin, H.; Liu, Z.; Han, X.; Wu, R. Two-Dimensional Tantalum Carbide (MXenes) Composite Nanosheets for Multiple Imaging-Guided Photothermal Tumor Ablation. *ACS Nano* **2017**, *11*, 12696–12712.
- (227) Xu, B.; Zhu, M.; Zhang, W.; Zhen, X.; Pei, Z.; Xue, Q.; Zhi, C.; Shi, P. Ultrathin MXene-Micropattern-Based Field-Effect Transistor for Probing Neural Activity. *Adv. Mater.* **2016**, *28*, 3333–3339.
- (228) Dai, C.; Lin, H.; Xu, G.; Liu, Z.; Wu, R.; Chen, Y. Biocompatible 2D Titanium Carbide (MXenes) Composite Nanosheets for pH-Responsive MRI-Guided Tumor Hyperthermia. *Chem. Mater.* **2017**, *29*, 8637–8652.
- (229) Lin, H.; Gao, S.; Dai, C.; Chen, Y.; Shi, J. Two-Dimensional Biodegradable Niobium Carbide (MXene) for Photothermal Tumor Eradication in NIR-I and NIR-II Bio-Windows. *J. Am. Chem. Soc.* **2017**, *139*, 16235–16247.
- (230) Rasool, K.; Mahmoud, K. A.; Johnson, D. J.; Helal, M.; Berdiyrov, G. R.; Gogotsi, Y. Efficient Antibacterial Membrane based on Two-Dimensional Ti₃C₂T_x (MXene) Nanosheets. *Sci. Rep.* **2017**, *7*, 1598.
- (231) Pandey, R. P.; Rasool, K.; Madhavan, V. E.; Aissa, B.; Gogotsi, Y.; Mahmoud, K. A. Ultrahigh-Flux and Fouling-Resistant Membrane Based on Layered Silver/MXene(Ti₃C₂T_x) Nanosheets. *J. Mater. Chem. A* **2018**, *6*, 3522–3533.
- (232) Nasrallah, G.; Al-Asmakh, M.; Rasool, K.; Mahmoud, K. A. Ecotoxicological Assessment of Ti₃C₂T_x (MXene) Using Zebrafish Embryo Model. *Environ. Sci.: Nano* **2018**, *5*, 1002–1011.
- (233) Naicker, S.; Yang, C.-W.; Hwang, S.-J.; Liu, B.-C.; Chen, J.-H.; Jha, V. The Novel Coronavirus 2019 Epidemic and Kidneys. *Kidney Int.* **2020**, *97*, 824–828.
- (234) 2018 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States; Bethesda, MD, 2018.
- (235) Meng, F.; Seredych, M.; Chen, C.; Gura, V.; Mikhailovsky, S.; Sandeman, S.; Ingavle, G.; Ozulumba, T.; Miao, L.; Anasori, B.; Gogotsi, Y. MXene Sorbents for Removal of Urea from Dialysate: A Step toward the Wearable Artificial Kidney. *ACS Nano* **2018**, *12*, 10518–10528.
- (236) Hojs, N.; Fissell, W. H.; Roy, S. Ambulatory Hemodialysis-Technology Landscape and Potential for Patient-Centered Treatment. *Clin. J. Am. Soc. Nephrol.* **2020**, *15*, 152–159.
- (237) Capua, I.; Cattoli, G. One Health (r)Evolution: Learning from the Past To Build a New Future. *Viruses* **2018**, *10*, 725.
- (238) Why Interdisciplinary Research Matters. *Nature* **2015**, *525*, 305.